Astrocytoma: Neoplasms of the brain and spinal cord derived from glial cells which vary from histologically benign forms to highly anaplastic and malignant tumors. Fibrillary astrocytomas are the most common type and may be classified in order of increasing malignancy (grades I through IV). In the first two decades of life, astrocytomas tend to originate in the cerebellar hemispheres; in adults, they most frequently arise in the cerebrum and frequently undergo malignant transformation. (From Devita et al., Cancer: Principles and Practice of Oncology, 5th ed, pp2013-7; Holland et al., Cancer Medicine, 3d ed, p1082)Brain Neoplasms: Neoplasms of the intracranial components of the central nervous system, including the cerebral hemispheres, basal ganglia, hypothalamus, thalamus, brain stem, and cerebellum. Brain neoplasms are subdivided into primary (originating from brain tissue) and secondary (i.e., metastatic) forms. Primary neoplasms are subdivided into benign and malignant forms. In general, brain tumors may also be classified by age of onset, histologic type, or presenting location in the brain.Hypothalamic Neoplasms: Benign and malignant tumors of the HYPOTHALAMUS. Pilocytic astrocytomas and hamartomas are relatively frequent histologic types. Neoplasms of the hypothalamus frequently originate from adjacent structures, including the OPTIC CHIASM, optic nerve (see OPTIC NERVE NEOPLASMS), and pituitary gland (see PITUITARY NEOPLASMS). Relatively frequent clinical manifestations include visual loss, developmental delay, macrocephaly, and precocious puberty. (From Devita et al., Cancer: Principles and Practice of Oncology, 5th ed, p2051)Glioblastoma: A malignant form of astrocytoma histologically characterized by pleomorphism of cells, nuclear atypia, microhemorrhage, and necrosis. They may arise in any region of the central nervous system, with a predilection for the cerebral hemispheres, basal ganglia, and commissural pathways. Clinical presentation most frequently occurs in the fifth or sixth decade of life with focal neurologic signs or seizures.Optic Nerve Neoplasms: Benign and malignant neoplasms that arise from the optic nerve or its sheath. OPTIC NERVE GLIOMA is the most common histologic type. Optic nerve neoplasms tend to cause unilateral visual loss and an afferent pupillary defect and may spread via neural pathways to the brain.Glioma: Benign and malignant central nervous system neoplasms derived from glial cells (i.e., astrocytes, oligodendrocytes, and ependymocytes). Astrocytes may give rise to astrocytomas (ASTROCYTOMA) or glioblastoma multiforme (see GLIOBLASTOMA). Oligodendrocytes give rise to oligodendrogliomas (OLIGODENDROGLIOMA) and ependymocytes may undergo transformation to become EPENDYMOMA; CHOROID PLEXUS NEOPLASMS; or colloid cysts of the third ventricle. (From Escourolle et al., Manual of Basic Neuropathology, 2nd ed, p21)Supratentorial Neoplasms: Primary and metastatic (secondary) tumors of the brain located above the tentorium cerebelli, a fold of dura mater separating the CEREBELLUM and BRAIN STEM from the cerebral hemispheres and DIENCEPHALON (i.e., THALAMUS and HYPOTHALAMUS and related structures). In adults, primary neoplasms tend to arise in the supratentorial compartment, whereas in children they occur more frequently in the infratentorial space. Clinical manifestations vary with the location of the lesion, but SEIZURES; APHASIA; HEMIANOPSIA; hemiparesis; and sensory deficits are relatively common features. Metastatic supratentorial neoplasms are frequently multiple at the time of presentation.Dictionaries, MedicalDictionaries as Topic: Lists of words, usually in alphabetical order, giving information about form, pronunciation, etymology, grammar, and meaning.Crowdsourcing: Social media model for enabling public involvement and recruitment in participation. Use of social media to collect feedback and recruit volunteer subjects.Terminology as Topic: The terms, expressions, designations, or symbols used in a particular science, discipline, or specialized subject area.Dictionaries, ChemicalNeurology: A medical specialty concerned with the study of the structures, functions, and diseases of the nervous system.Thalamic Diseases: Disorders of the centrally located thalamus, which integrates a wide range of cortical and subcortical information. Manifestations include sensory loss, MOVEMENT DISORDERS; ATAXIA, pain syndromes, visual disorders, a variety of neuropsychological conditions, and COMA. Relatively common etiologies include CEREBROVASCULAR DISORDERS; CRANIOCEREBRAL TRAUMA; BRAIN NEOPLASMS; BRAIN HYPOXIA; INTRACRANIAL HEMORRHAGES; and infectious processes.Magnetic Resonance Imaging: Non-invasive method of demonstrating internal anatomy based on the principle that atomic nuclei in a strong magnetic field absorb pulses of radiofrequency energy and emit them as radiowaves which can be reconstructed into computerized images. The concept includes proton spin tomographic techniques.Prognosis: A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations.Brain: The part of CENTRAL NERVOUS SYSTEM that is contained within the skull (CRANIUM). Arising from the NEURAL TUBE, the embryonic brain is comprised of three major parts including PROSENCEPHALON (the forebrain); MESENCEPHALON (the midbrain); and RHOMBENCEPHALON (the hindbrain). The developed brain consists of CEREBRUM; CEREBELLUM; and other structures in the BRAIN STEM.Anisocoria: Unequal pupil size, which may represent a benign physiologic variant or a manifestation of disease. Pathologic anisocoria reflects an abnormality in the musculature of the iris (IRIS DISEASES) or in the parasympathetic or sympathetic pathways that innervate the pupil. Physiologic anisocoria refers to an asymmetry of pupil diameter, usually less than 2mm, that is not associated with disease.Plasmapheresis: Procedure whereby plasma is separated and extracted from anticoagulated whole blood and the red cells retransfused to the donor. Plasmapheresis is also employed for therapeutic use.Myoclonus: Involuntary shock-like contractions, irregular in rhythm and amplitude, followed by relaxation, of a muscle or a group of muscles. This condition may be a feature of some CENTRAL NERVOUS SYSTEM DISEASES; (e.g., EPILEPSY, MYOCLONIC). Nocturnal myoclonus is the principal feature of the NOCTURNAL MYOCLONUS SYNDROME. (From Adams et al., Principles of Neurology, 6th ed, pp102-3).Guillain-Barre Syndrome: An acute inflammatory autoimmune neuritis caused by T cell- mediated cellular immune response directed towards peripheral myelin. Demyelination occurs in peripheral nerves and nerve roots. The process is often preceded by a viral or bacterial infection, surgery, immunization, lymphoma, or exposure to toxins. Common clinical manifestations include progressive weakness, loss of sensation, and loss of deep tendon reflexes. Weakness of respiratory muscles and autonomic dysfunction may occur. (From Adams et al., Principles of Neurology, 6th ed, pp1312-1314)Stereotaxic Techniques: Techniques used mostly during brain surgery which use a system of three-dimensional coordinates to locate the site to be operated on.Respiratory Insufficiency: Failure to adequately provide oxygen to cells of the body and to remove excess carbon dioxide from them. (Stedman, 25th ed)Encyclopedias as Topic: Works containing information articles on subjects in every field of knowledge, usually arranged in alphabetical order, or a similar work limited to a special field or subject. (From The ALA Glossary of Library and Information Science, 1983)Oligodendroglioma: A relatively slow-growing glioma that is derived from oligodendrocytes and tends to occur in the cerebral hemispheres, thalamus, or lateral ventricle. They may present at any age, but are most frequent in the third to fifth decades, with an earlier incidence peak in the first decade. Histologically, these tumors are encapsulated, relatively avascular, and tend to form cysts and microcalcifications. Neoplastic cells tend to have small round nuclei surrounded by unstained nuclei. The tumors may vary from well-differentiated to highly anaplastic forms. (From DeVita et al., Cancer: Principles and Practice of Oncology, 5th ed, p2052; Adams et al., Principles of Neurology, 6th ed, p655)Wheelchairs: Chairs mounted on wheels and designed to be propelled by the occupant.Kyphosis: Deformities of the SPINE characterized by an exaggerated convexity of the vertebral column. The forward bending of the thoracic region usually is more than 40 degrees. This deformity sometimes is called round back or hunchback.Scoliosis: An appreciable lateral deviation in the normally straight vertical line of the spine. (Dorland, 27th ed)Survivors: Persons who have experienced a prolonged survival after serious disease or who continue to live with a usually life-threatening condition as well as family members, significant others, or individuals surviving traumatic life events.Chin: The anatomical frontal portion of the mandible, also known as the mentum, that contains the line of fusion of the two separate halves of the mandible (symphysis menti). This line of fusion divides inferiorly to enclose a triangular area called the mental protuberance. On each side, inferior to the second premolar tooth, is the mental foramen for the passage of blood vessels and a nerve.Morphine: The principal alkaloid in opium and the prototype opiate analgesic and narcotic. Morphine has widespread effects in the central nervous system and on smooth muscle.Urogenital Neoplasms: Tumors or cancer of the UROGENITAL SYSTEM in either the male or the female.Periodicals as Topic: A publication issued at stated, more or less regular, intervals.Access to Information: Individual's rights to obtain and use information collected or generated by others.Medical Oncology: A subspecialty of internal medicine concerned with the study of neoplasms.Journal Impact Factor: A quantitative measure of the frequency on average with which articles in a journal have been cited in a given period of time.Bibliometrics: The use of statistical methods in the analysis of a body of literature to reveal the historical development of subject fields and patterns of authorship, publication, and use. Formerly called statistical bibliography. (from The ALA Glossary of Library and Information Science, 1983)Area Under Curve: A statistical means of summarizing information from a series of measurements on one individual. It is frequently used in clinical pharmacology where the AUC from serum levels can be interpreted as the total uptake of whatever has been administered. As a plot of the concentration of a drug against time, after a single dose of medicine, producing a standard shape curve, it is a means of comparing the bioavailability of the same drug made by different companies. (From Winslade, Dictionary of Clinical Research, 1992)Half-Life: The time it takes for a substance (drug, radioactive nuclide, or other) to lose half of its pharmacologic, physiologic, or radiologic activity.Administration, Oral: The giving of drugs, chemicals, or other substances by mouth.Biological Availability: The extent to which the active ingredient of a drug dosage form becomes available at the site of drug action or in a biological medium believed to reflect accessibility to a site of action.Metabolic Clearance Rate: Volume of biological fluid completely cleared of drug metabolites as measured in unit time. Elimination occurs as a result of metabolic processes in the kidney, liver, saliva, sweat, intestine, heart, brain, or other site.Drug Interactions: The action of a drug that may affect the activity, metabolism, or toxicity of another drug.Giant Cells: Multinucleated masses produced by the fusion of many cells; often associated with viral infections. In AIDS, they are induced when the envelope glycoprotein of the HIV virus binds to the CD4 antigen of uninfected neighboring T4 cells. The resulting syncytium leads to cell death and thus may account for the cytopathic effect of the virus.Hearing Loss: A general term for the complete or partial loss of the ability to hear from one or both ears.Hearing: The ability or act of sensing and transducing ACOUSTIC STIMULATION to the CENTRAL NERVOUS SYSTEM. It is also called audition.Hearing Aids: Wearable sound-amplifying devices that are intended to compensate for impaired hearing. These generic devices include air-conduction hearing aids and bone-conduction hearing aids. (UMDNS, 1999)Hearing Tests: Part of an ear examination that measures the ability of sound to reach the brain.Hypermedia: Computerized compilations of information units (text, sound, graphics, and/or video) interconnected by logical nonlinear linkages that enable users to follow optimal paths through the material and also the systems used to create and display this information. (From Thesaurus of ERIC Descriptors, 1994)Adaptation, Psychological: A state of harmony between internal needs and external demands and the processes used in achieving this condition. (From APA Thesaurus of Psychological Index Terms, 8th ed)Research: Critical and exhaustive investigation or experimentation, having for its aim the discovery of new facts and their correct interpretation, the revision of accepted conclusions, theories, or laws in the light of newly discovered facts, or the practical application of such new or revised conclusions, theories, or laws. (Webster, 3d ed)Information Systems: Integrated set of files, procedures, and equipment for the storage, manipulation, and retrieval of information.Internet: A loose confederation of computer communication networks around the world. The networks that make up the Internet are connected through several backbone networks. The Internet grew out of the US Government ARPAnet project and was designed to facilitate information exchange.

Expression and tissue localization of membrane-type 1, 2, and 3 matrix metalloproteinases in human astrocytic tumors. (1/1796)

Three different membrane-type matrix metalloproteinases (MT1-, MT2-, and MT3-MMPs) are known to activate in vitro the zymogen of MMP-2 (pro-MMP-2, progelatinase A), which is one of the key MMPs in invasion and metastasis of various cancers. In the present study, we have examined production and activation of pro-MMP-2, expression of MT1-, MT2-, and MT3-MMPs and their correlation with pro-MMP-2 activation, and localization of MMP-2, MT1-MMP, and MT2-MMP in human astrocytic tumors. The sandwich enzyme immunoassay demonstrates that the production levels of pro-MMP-2 in the anaplastic astrocytomas and glioblastomas are significantly higher than that in the low-grade astrocytomas (P<0.05 and P<0.01, respectively), metastatic brain tumors (P<0.05), or normal brains (P<0.01). Gelatin zymography indicates that the pro-MMP-2 activation ratio is significantly higher in the glioblastomas than in other astrocytic tumors (P<0.01), metastatic brain tumors (P<0.01), and normal brains (P<0.01). The quantitative reverse transcription polymerase chain reaction analyses demonstrate that MT1-MMP and MT2-MMP are expressed predominantly in glioblastoma tissues (17/17 and 12/17 cases, respectively), and their expression levels increase significantly as tumor grade increases. MT3-MMP is detectable in both astrocytic tumor and normal brain tissues, but the mean expression level is approximately 50-fold lower compared with that of MT1-MMP and MT2-MMP in the glioblastomas. The activation ratio of pro-MMP-2 correlates directly with the expression levels of MT1-MMP and MT2-MMP but not MT3-MMP. In situ hybridization indicates that neoplastic astrocytes express MT1-MMP and MT2-MMP in the glioblastoma tissues (5/5 cases and 5/5 cases, respectively). Immunohistochemically, MT1-MMP and MT2-MMP are localized to the neoplastic astrocytes in glioblastoma samples (17/17 cases and 12/17 cases, respectively), which are also positive for MMP-2. In situ zymography shows gelatinolytic activity in the glioblastoma tissues but not in the normal brain tissues. These results suggest that both MT1-MMP and MT2-MMP play a key role in the activation of pro-MMP-2 in the human malignant astrocytic tumors and that the gelatinolytic activity is involved in the astrocytic tumor invasion.  (+info)

Early induction of angiogenetic signals in gliomas of GFAP-v-src transgenic mice. (2/1796)

Angiogenesis is a prerequisite for solid tumor growth. Glioblastoma multiforme, the most common malignant brain tumor, is characterized by extensive vascular proliferation. We previously showed that transgenic mice expressing a GFAP-v-src fusion gene in astrocytes develop low-grade astrocytomas that progressively evolve into hypervascularized glioblastomas. Here, we examined whether tumor progression triggers angiogenetic signals. We found abundant transcription of vascular endothelial growth factor (VEGF) in neoplastic astrocytes at surprisingly early stages of tumorigenesis. VEGF and v-src expression patterns were not identical, suggesting that VEGF activation was not only dependent on v-src. Late-stage gliomas showed perinecrotic VEGF up-regulation similarly to human glioblastoma. Expression patterns of the endothelial angiogenic receptors flt-1, flk-1, tie-1, and tie-2 were similar to those described in human gliomas, but flt-1 was expressed also in neoplastic astrocytes, suggesting an autocrine role in tumor growth. In crossbreeding experiments, hemizygous ablation of the tumor suppressor genes Rb and p53 had no significant effect on the expression of VEGF, flt-1, flk-1, tie-1, and tie-2. Therefore, expression of angiogenic signals is an early event during progression of GFAP-v-src tumors and precedes hypervascularization. Given the close similarities in the progression pattern between GFAP-v-src and human gliomas, the present results suggest that these mice may provide a useful tool for antiangiogenic therapy research.  (+info)

Clinical importance of c-Met protein expression in high grade astrocytic tumors. (3/1796)

The clinical importance of the expression of c-Met protein, the receptor of hepatocyte growth factor/scatter factor, was evaluated in neuroepithelial tissue tumors. c-Met immunohistochemistry was performed using the streptavidin-biotin-peroxidase complex method with anti-c-Met polyclonal antibody. Specimens were classified as c-Met negative (< 30%) or c-Met positive (> or = 30%) according to the proportion of immunopositive cells under microscopic examination. All c-Met-positive cases occurred in high grade astrocytic tumors, not in other neuroepithelial tissue tumors. Most c-Met-positive astrocytic tumors were classified histologically as high grade tumors. Epidermal growth factor-receptor (EGFR) and MIB-1 immunohistochemistry were also performed for high grade astrocytic tumors. Survival analysis was performed for patients with these tumors with variables including c-Met positivity, EGFR positivity, and MIB-1 labeling index. Positivity of c-Met was independent from EGFR positivity and MIB-1 labeling index, and the c-Met-positive group showed a significant shorter survival (p < 0.05). c-Met immunopositivity may be a parameter of biological aggressiveness in high grade astrocytic tumors. Examination of c-Met expression in astrocytic tumors provides significant clinical information, especially as a prognostic factor.  (+info)

Secondary glioblastoma remarkably reduced by steroid administration after anaplastic transformation from gliomatosis cerebri--case report. (4/1796)

A 45-year-old female presented with gliomatosis cerebri manifesting as hemiballismus-like involuntary movement in the arm, motor weakness in the leg, and hypesthesia in her left side. Computed tomography showed only diffuse swelling of the right cerebral hemisphere, but T2-weighted magnetic resonance imaging revealed a diffuse lesion spreading from the right thalamus to the temporal, parietal, and occipital lobes on the same side. No abnormal enhancement was recognized. Cerebral angiography showed no specific finding. A right occipital lobectomy was performed to confirm the diagnosis of gliomatosis cerebri. Anaplastic transformation was recognized 5 months later. The disease did not resolve with radiation or interferon administration, but steroid therapy achieved remarkably effective tumor regression. The patient died due to pneumonia. Autopsy showed the features of diffuse glioblastoma. Steroid therapy may be an effective treatment for gliomatosis cerebri before the terminal stage.  (+info)

Requirements for measles virus induction of RANTES chemokine in human astrocytoma-derived U373 cells. (5/1796)

Interferons and chemokines play a critical role in regulating the host response to viral infection. Measles virus, a member of the Paramyxoviridae family, induces RANTES expression by astrocytes. We have examined the mechanism of this induction in U373 cells derived from a human astrocytoma. RANTES was induced in a dose- and time-dependent manner by measles virus infection. Inhibition of receptor binding by the anti-CD46 antibody TRA-2.10 and of virus-membrane fusion by the tripeptide X-Phe-Phe-Gly reduced RANTES expression. Formalin-inactivated virus, which can bind but not fuse, and extensively UV-irradiated virus, which can bind and fuse, were both ineffective. Therefore, virus binding to the cellular receptor CD46 and subsequent membrane fusion were necessary, but not sufficient, to induce RANTES. UV irradiation of virus for less than 10 min proportionally inhibited viral transcription and RANTES expression. RANTES induction was decreased in infected cells treated with ribavirin, which inhibits measles virus transcription. However, RANTES mRNA was superinduced by measles virus in the presence of cycloheximide. These data suggest that partial transcription of the viral genome is sufficient and necessary for RANTES induction, whereas viral protein synthesis and replication are not required. This hypothesis was supported by the fact that RANTES was induced through transient expression of the measles virus nucleocapsid gene but not by measles genes encoding P or L proteins or by leader RNA in A549 cells. Thus, transcription of specific portions of measles virus RNA, such as the nucleocapsid gene, appears able to generate the specific signaling required to induce RANTES gene expression.  (+info)

Persistent infection of human oligodendrocytic and neuroglial cell lines by human coronavirus 229E. (6/1796)

Human coronaviruses (HuCV) cause common colds. Previous reports suggest that these infectious agents may be neurotropic in humans, as they are for some mammals. With the long-term aim of providing experimental evidence for the neurotropism of HuCV and the establishment of persistent infections in the nervous system, we have evaluated the susceptibility of various human neural cell lines to acute and persistent infection by HuCV-229E. Viral antigen, infectious virus progeny and viral RNA were monitored during both acute and persistent infections. The astrocytoma cell lines U-87 MG, U-373 MG, and GL-15, as well as neuroblastoma SK-N-SH, neuroglioma H4, and oligodendrocytic MO3.13 cell lines, were all susceptible to an acute infection by HuCV-229E. The CHME-5 immortalized fetal microglial cell line was not susceptible to infection by this virus. The MO3.13 and H4 cell lines also sustained a persistent viral infection, as monitored by detection of viral antigen and infectious virus progeny. Sequencing of the S1 gene from viral RNA after approximately 130 days of infection showed two point mutations, suggesting amino acid changes during persistent infection of MO3.13 cells but none for H4 cells. Thus, persistent in vitro infection did not generate important changes in the S1 portion of the viral spike protein, which was shown for murine coronaviruses to bear hypervariable domains and to interact with cellular receptor. These results are consistent with the potential persistence of HuCV-229E in cells of the human nervous system, such as oligodendrocytes and possibly neurons, and the virus's apparent genomic stability.  (+info)

Simultaneous alterations of retinoblastoma and p53 protein expression in astrocytic tumors. (7/1796)

The genetic alterations frequently involved in glial malignancies are in the tumor suppressor genes, Rb and p53. An altered Rb expression or p53 overexpression is thought to indicate defective tumor suppression and subsequently more aggressive tumors. Therefore, to assess the alterations in the conjoint expression of Rb and p53 proteins in formalin fixed paraffin embedded sections, 64 astrocytic tumors were studied (16 astrocytomas,7 gemistocytic astrocytomas, 19 anaplastic astrocytomas and 22 glioblastomas) using the avidin biotin immunoperoxidase technique. Fifty two cases (81.25%) were found to be positive for p53 protein. Seventeen of these showed aberrant heterogenous staining for pRb, of which 7 were glioblastomas. Only one case of astrocytoma showed aberrant expression of both p53 and Rb. Thus, of the 64 tumors, simultaneous aberrant expression of both p53 and Rb was seen in 21.9% of cases. This was more commonly observed among glioblastoma cases (7/22). No statistical difference was found between the survival rate of heterogenous pRb and p53 positivity in different grades of tumors. In glioblastomas, the survival rate appeared to be less in patients expressing heterogenous pRb, but this was not statistically significant. These results lead us to suspect that p53 and pRb pathways are inactivated, either through mutation or as part of the neoplastic process in astrocytic tumors.  (+info)

Procarbazine and high-dose tamoxifen as a second-line regimen in recurrent high-grade gliomas: a phase II study. (8/1796)

PURPOSE: A phase II study was conducted in patients with high-grade gliomas that recurred after surgery plus radiotherapy and a first-line nitrosourea-based regimen. Our aim was to investigate the efficacy of procarbazine (PCB) combined with high-dose tamoxifen in relation to tumor control, toxicity, and time to progression (TTP). PATIENTS AND METHODS: Fifty-three patients were treated with procarbazine in repeated 30-day courses at 100 mg/m2/d plus tamoxifen 100 mg/d, with a 30-day interval between courses. Thirty-four patients had been pretreated with a first-line nitrosourea-based chemotherapy regimen (group A), and 19 patients had also been pretreated with a second-line chemotherapy regimen consisting of carboplatin and teniposide (group B). Twenty-one of the patients had also been procarbazine pretreated, whereas the remaining 32 patients were not procarbazine pretreated. RESULTS: The response was assessed in 51 patients, 28 of whom had glioblastoma multiforme (GBM) and 23 of whom had anaplastic astrocytoma (AA). There were two complete responses (CR) (4%) and 13 partial responses (PR) (25.5%). The overall response rate (CR + PR) was 29.5% (SE, 6.4; 95% confidence interval [CI], 23 to 35.8). Seventeen patients (32%) had stable disease (SE, 6.2; 95% CI, 21 to 33.6). The median TTP was 13 weeks for patients with GBM and 33 weeks for patients with AA (P = .006). The median survival time (MST) was 27 weeks for patients with GBM and 57 weeks for those with AA (P = .006). CONCLUSION: Combined PCB and tamoxifen as a second-line regimen gave a reasonably high response rate in patients with heavily pretreated high-grade gliomas. However, although it resulted in an improvement in the patients' quality of life and/or performance status, it was not followed by an increased TTP or MST.  (+info)

*Astrocyte

a b c d Astrocytomas. International RadioSurgery Association (2010). *^ a b Astrocytoma Tumors. American Association of ... Astrocytomas[edit]. Astrocytomas are primary intracranial tumors derived from astrocytes cells of the brain. It is also ... Pilocytic astrocytoma are Grade I tumors. They are considered benign and slow growing tumors. Pilocytic astrocytomas frequently ... Astrocytomas are divided into two categories: Low grade (I and II) and High Grade (III and IV). Low grade tumors are more ...

*CD30

Astrocytoma. *Glial fibrillary acidic protein. NC/Melanoma. *S100 protein. *Melanoma inhibitory activity ...

*Cathepsin D

Astrocytoma. *Glial fibrillary acidic protein. NC/Melanoma. *S100 protein. *Melanoma inhibitory activity ...

*Desmin

Astrocytoma. *Glial fibrillary acidic protein. NC/Melanoma. *S100 protein. *Melanoma inhibitory activity ...

*Astrocyte

a b c d Astrocytomas. International RadioSurgery Association (2010). *^ a b Astrocytoma Tumors. American Association of ... AstrocytomasEdit. Astrocytomas are primary intracranial tumors derived from astrocytes cells of the brain. It is also possible ... Pilocytic astrocytoma are Grade I tumors. They are considered benign and slow growing tumors. Pilocytic astrocytomas frequently ... Astrocytomas are divided into two categories: Low grade (I and II) and High Grade (III and IV). Low grade tumors are more ...

*Alcohol and cancer

Childhood astrocytomaEdit. Main article: Astrocytoma. A study concluded that foetal exposure to alcohol is not associated with ... "Gestational and familial risk factors for childhood astrocytoma: results of a case-control study" (PDF). Cancer Research. 50 ...

*Neurooncology

1. Malignant Astrocytomas. Malignant astrocytomas are the most common primary brain tumors in adults. Malignant astrocytomas ... 2. Other Astrocytomas. Tumors of presumed or known astrocytic lineage other than the malignant astrocytomas include a variety ... Some data have shown that oligodendroglial tumors were more likely to be located in frontal lobe, whereas astrocytomas were ... Primary spinal cord tumors are uncommon and most are either astrocytomas or ependymomas.[10] ...

*Astrocyte

Pilocytic astrocytoma are Grade I tumors. They are considered benign and slow growing tumors. Pilocytic astrocytomas frequently ... It is also possible that glial progenitors or neural stem cells give rise to astrocytomas. Astrocytomas are brain tumors that ... Astrocytomas. International RadioSurgery Association (2010). Astrocytoma Tumors. American Association of Neurological Surgeons ... Astrocytomas are divided into two categories: Low grade (I and II) and High Grade (III and IV). Low grade tumors are more ...

*Brain tumor

Anaplastic astrocytoma, Astrocytoma, Central neurocytoma, Choroid plexus carcinoma, Choroid plexus papilloma, Choroid plexus ... The most common types of primary tumors in adults are meningiomas (usually benign), and astrocytomas such as glioblastomas. In ... The incidence of low-grade astrocytoma has not been shown to vary significantly with nationality. However, studies examining ... Jallo GI, Benardete EA (January 2010). "Low-Grade Astrocytoma". Archived from the original on 27 July 2010. "CANCERMondial". ...

*Grading of the tumors of the central nervous system

Grade 1 tumors are benign astrocytomas. Grade 2 tumors are low-grade astrocytomas. Grade 3 tumors are anaplastic astrocytomas. ... The St Anne-Mayo grading system also is used to grade astrocytomas; however, this system uses four morphologic criteria to ... Kim TS, Halliday AL, Hedley W, Convery K (1991). Correlates of survival and the Daumas-Duport grading system for astrocytomas. ... Daumas-Duport C, Scheithauer B, O'Fallon J, Kelly P (1988). Grading of astrocytomas. A simple and reproducible method. Cancer ...

*Brain tumor

Anaplastic astrocytoma, Astrocytoma, Central neurocytoma, Choroid plexus carcinoma, Choroid plexus papilloma, Choroid plexus ... The incidence of low-grade astrocytoma has not been shown to vary significantly with nationality. However, studies examining ... and astrocytomas such as glioblastomas.[1] In children, the most common type is a malignant medulloblastoma.[3] Diagnosis is ... the WHO system established a four-tiered histologic grading guideline for astrocytomas that assigns a grade from 1 to 4, with 1 ...

*Brain tumor

Anaplastic astrocytoma, Astrocytoma, Central neurocytoma, Choroid plexus carcinoma, Choroid plexus papilloma, Choroid plexus ... Loss of TP53 and ATRX characterizes astrocytomas. *Genes EFGR, TERT, and PTEN, are commonly altered in gliomas and are useful ... The most common brain tumor types in children (0-14) are: pilocytic astrocytoma, malignant glioma, medulloblastoma, neuronal ... The incidence of low-grade astrocytoma has not been shown to vary significantly with nationality. However, studies examining ...

*Alternating electric field therapy

Johnson, Derek (August 2014). "Medical Management of High-Grade Astrocytoma: Current and Emerging Therapies". Seminars in ... "Initial postoperative therapy for glioblastoma and anaplastic astrocytoma". UpToDate. Retrieved 26 December 2014. "Disruption ...

*Dysembryoplastic neuroepithelial tumour

Pilocytic astrocytoma Oligodendroglioma Focal cortical dysplasia Thom, Maria; Toma, Ahmed; An, Shu; Martinian, Lillian; ...

*WHO classification of tumours of the central nervous system

Astrocytic tumours (Astrocytomas, a type of brain tumor) 1.1.1 Pilocytic astrocytoma (ICD-O 9421/1, WHO grade I) 1.1.1a ... 1.1.4 Diffuse astrocytoma (ICD-O 9400/3, WHO grade II) 1.1.5 Anaplastic astrocytoma (ICD-O 9401/3, WHO grade III) 1.1.6. ... Pilomyxoid astrocytoma (ICD-O 9425/3, WHO grade II) 1.1.2 Subependymal giant cell astrocytoma (ICD-O 9384/1, WHO grade I) 1.1.3 ... AFIP Course Syllabus - Astrocytoma WHO Grading Lecture Handout. ... 1.7.2 Desmoplastic infantile astrocytoma/ganglioglioma (ICD-O ...

*RTN3

2004). "Overexpression of human reticulon 3 (hRTN3) in astrocytoma". Clin. Neuropathol. 23 (1): 1-7. PMID 14986927. Hu Y, Fang ...

*Oligodendroglioma

However compared to the more common astrocytomas, they are slowly growing with prolonged survival. In one series, median ... Oligodendrogliomas must be differentiated from the more common astrocytoma. Non-classical variants and combined tumors of both ... are more common in classic oligodendrogliomas than in either astrocytomas or oligoastrocytomas. In one study, classic ... tumors with which they are often confused due to their monotonous round cell appearance include pilocytic astrocytoma, central ...

*Hypermetabolism

Astrocytoma: Manifestation: Causes hypermetabolic lesions in the brain Since hypermetabolism itself is a symptom and not an ... "Diagnosis of Recurrent Astrocytoma with Fludeoxyglucose F18 PET Scanning". The New England Journal of Medicine. Retrieved 29 ...

*Wirginia Maixner

"Development of a pilocytic astrocytoma in a dysembryoplastic neuroepithelial tumor. Case report", Journal of Neurosurgery, 2007 ...

*Aldo-keto reductase family 1, member A1

... and 4-hydroxynonenal-induced cytotoxicity in human 1321N1 astrocytoma cells]". Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi = Chinese ...

*Cataplexy

Some of the tumors include astrocytoma, glioblastoma, glioma, and subependynoma. These lesions can be visualized with brain ...

*Gap junction

May 1996). "Protein and messenger RNA expression of connexin43 in astrocytomas: implications in brain tumor gene therapy". J. ...

*Obama, Fukui

"Ultrastructure of capillary endothelium in pilocytic astrocytomas". Brain Tumor Pathol. 21 (1): 23-26. doi:10.1007/BF02482173 ...

*Muir-Torre syndrome

... and a malignant astrocytoma". Dermatology Online Journal. 18 (5): 3. PMID 22630573. Grandhi R, Deibert CP, Pirris SM, Lembersky ...

*NRN1

Overexpression of the encoded protein may be associated with astrocytoma progression. Alternative splicing results in multiple ... and angiogenesis in human astrocytoma". Med. Oncol. 28 (3): 907-12. doi:10.1007/s12032-010-9537-9. PMID 20405246. Akten B, Kye ...

*Primidone

"Primidone-induced hyperammonemic encephalopathy in a patient with cerebral astrocytoma" (PDF). Journal of Clinical Neuroscience ... early 2002 in a patient who had been stable on primidone monotherapy for five years before undergoing surgery for astrocytoma, ...
MMP-2 production by tumor cells has been demonstrated to play a fundamental role in ECM degradation and tumor cell invasion (for review see 5 . The recent finding of reduced tumor progression in MMP-2-deficient mice (57) highlights the importance of this molecule. In this study, we wished to determine how MMP-2 gene expression is regulated in human astroglioma cells, as a strong correlation has been observed between astroglioma invasion and MMP-2 expression (17, 19, 20, 22, 23, 27). Our results indicate that two cytokines, TNF-α and IFN-γ, partially inhibit MMP-2 gene expression and can function together in an additive manner for near-complete inhibition of MMP-2 expression in human astroglioma cells. TNF-α/IFN-γ inhibition of MMP-2 expression was observed at several levels: on gelatinolytic activity as determined by zymography, on protein expression (both ProMMP-2 and activated MMP-2) as assessed by immunoblotting, on MMP-2 mRNA expression, and on MMP-2 promoter activity. Our results also ...
Find the best malignant astrocytoma doctors in Delhi NCR. Get guidance from medical experts to select malignant astrocytoma specialist in Delhi NCR from trusted hospitals - credihealth.com
Astrocytomas are a type of cancer of the brain. They originate in a particular kind of glial cells, star-shaped brain cells in the cerebrum called astrocytes. This type of tumor does not usually spread outside the brain and spinal cord and it does not usually affect other organs. Astrocytomas are the most common glioma and can occur in most parts of the brain and occasionally in the spinal cord. Within the astrocytomas, there are two broad classes recognized in literature, those with: Narrow zones of infiltration (mostly noninvasive tumors; e.g., pilocytic astrocytoma, subependymal giant cell astrocytoma, pleomorphic xanthoastrocytoma), that often are clearly outlined on diagnostic images Diffuse zones of infiltration (e.g., high-grade astrocytoma, anaplastic astrocytoma, glioblastoma), that share various features, including the ability to arise at any location in the CNS (Central Nervous System), but with a preference for the cerebral hemispheres; they occur usually in adults; and an intrinsic ...
View details of top juvenile pilocytic astrocytoma hospitals in New Delhi. Get guidance from medical experts to select best juvenile pilocytic astrocytoma hospital in New Delhi
Find people with Juvenile Pilocytic Astrocytoma through the map. Connect with them and share experiences. Join the Juvenile Pilocytic Astrocytoma community.
A case of anaplastic pleomorphic xanthoastrocytoma (PXA) in a 9-year-old girl is reported. Histological features of PXAs are cellular pleomorphism of GFAP-positive cells, with intracytoplasmic lipidic vacuoles and a reticulin network, bizarre giant cells, low mitotic activity, and lack of necrosis and of endothelial vascular proliferations. These tumors are generally reported to have a favorable postoperative course. In our case, a poor clinical prognosis and spread of the illness through the CSF was observed. Immunohistochemical features of the tumor, which were histologically anaplastic in nature, were analyzed. There were small foci of necrosis in the sections of the material obtained at the first operation and extensive necrosis in that from the second operation, although the patient had not received radiotherapy between the operations. The presence of necrosis in PXA is an uncommon and significant feature. It predicts the poor prognosis seen in this case, and therefore this report strongly supports
Anaplastic astrocytoma is a rare WHO grade III type of astrocytoma, which is a type of cancer of the brain. In the United States, the annual incidence rate for Anaplastic astrocytoma is 0.44 per 100,000 persons Anaplastic astrocytomas fall under the category of high grade gliomas (WHO grade III-IV), which are pathologically undifferentiated gliomas that carry a poor clinical prognosis. Unlike glioblastomas (WHO grade IV), anaplastic astrocytomas lack vascular proliferation and necrosis on pathologic evaluation. Compared to grade II tumors, anaplastic astrocytomas are more cellular, demonstrate more atypia, and mitoses are seen. Initial presenting symptoms most commonly are headache, depressed mental status, focal neurological deficits, and/or seizures. The growth rate and mean interval between onset of symptoms and diagnosis is approximately 1.5-2 years but is highly variable, being intermediate between that of low-grade astrocytomas and glioblastomas. Seizures are less common among patients ...
TY - JOUR. T1 - Adult Pilocytic Astrocytoma. T2 - An Institutional Series and Systematic Literature Review for Extent of Resection and Recurrence. AU - Bond, Kamila M.. AU - Hughes, Joshua D.. AU - Porter, Amanda L.. AU - Orina, Josiah. AU - Fang, Shanna. AU - Parney, Ian F.. PY - 2018/2/1. Y1 - 2018/2/1. N2 - Introduction Pilocytic astrocytoma is a classically benign tumor that most often affects pediatric patients. Rarely, it occurs during adulthood. We present a case series and systematic literature review of adult pilocytic astrocytoma (APA) to examine the clinical presentation, extent of resection, and recurrence rate associated with this tumor in this population. Materials and Methods Our institutional records were retrospectively reviewed for cases of pilocytic astrocytoma in adults. A PubMed search identified English-language studies of pathology-proven APA. A meta-analysis was performed to determine the relationship between extent of tumor resection and recurrence. Results Forty-six ...
TY - JOUR. T1 - Prognostic significance of multiple kallikreins in high-grade astrocytoma. AU - Drucker, Kristen L.. AU - Gianinni, Caterina. AU - Decker, Paul A.. AU - Diamandis, Eleftherios P.. AU - Scarisbrick, Isobel A. PY - 2015/8/1. Y1 - 2015/8/1. N2 - Background: Kallikreins have clinical value as prognostic markers in a subset of malignancies examined to date, including kallikrein 3 (prostate specific antigen) in prostate cancer. We previously demonstrated that kallikrein 6 is expressed at higher levels in grade IV compared to grade III astrocytoma and is associated with reduced survival of GBM patients. Methods: In this study we determined KLK1, KLK6, KLK7, KLK8, KLK9 and KLK10 protein expression in two independent tissue microarrays containing 60 grade IV and 8 grade III astrocytoma samples. Scores for staining intensity, percent of tumor stained and immunoreactivity scores (IR, product of intensity and percent) were determined and analyzed for correlation with patient survival. ...
Astrocytes are the most common type of cell in the central nervous system. They perform many essential roles and make up the supportive tissue of the brain. When there is a defect in an astrocyte that causes it to grow out of control, the brain tumor that forms is called an astrocytoma.. Astrocytomas come in four major subtypes: pilocytic astrocytoma (grade 1), fibrillary astrocytoma (grade 2), anaplastic astrocytoma (grade 3), and glioblastoma multiforme (grade 4).. Low-grade astrocytomas (grades 1 and 2), seen more often in kids and young adults, are highly curable because they usually grow slowly, dont spread, and usually are fairly easy to remove unless found in areas where surgery would be difficult. After surgery, theres a chance that chemotherapy or radiation wont be needed.. High-grade astrocytomas (grades 3 and 4), which tend to be seen more in adults, are more aggressive and invade deeper into the tissues. This makes them more difficult to treat. Treatment usually includes surgery, ...
Presence of IDH1 mutation determines best treatment for malignant astrocytomas. Astrocytomas are the most common malignant brain tumors. While most patients tumors prove to be quite aggressive, outcomes overall can vary widely, with some patients surviving for many years. Now a new study has found that malignant astrocytoma patients whose tumors carry a specific genetic mutation benefit greatly from surgical removal of the largest possible amount of tumor. Preliminary results of the study were reported at the 2012 American Society of Clinical Oncology meeting, and the teams full report appears in the January issue of the journal Neuro-Oncology. A type of glioma, astrocytomas include the highly aggressive glioblastoma and the less aggressive but still dangerous anaplastic astrocytoma.. "We found that the benefit of surgery and how aggressively the surgery should be done depend, in large part, on whether or not patients tumors have the mutated form of the IDH1 gene," says Daniel Cahill, MD, ...
Malignant astrocytomas, which are highly invasive, vascular neoplasms, compose the majority of nervous system tumors in humans. Elevated expression of fibroblast growth factors (FGFs) in astrocytomas has implicated the FGF family of mitogens in the initiation and progression of astrocyte-derived tumors. In this study, we demonstrated that human astrocytomas undergo parallel changes in FGF-receptor (FGFR) expression during their progression from a benign to a malignant phenotype. FGFR type 2 (BEK) expression was abundant in normal white matter and in all low-grade astrocytomas but was not seen in malignant astrocytomas. Conversely, FGFR type 1 (FLG) expression was absent or barely detectable in normal white matter but was significantly elevated in malignant astrocytomas. Malignant astrocytomas also expressed an alternatively spliced form of FGFR-1 (FGFR-1 beta) containing two immunoglobulin-like disulfide loops, whereas normal human adult and fetal brains expressed a receptor form (FGFR-1 alpha) ...
Background Astrocytomas are the most aggressive and common human brain tumors characterized by their highly invasive development. of miR-335 in C6 cells enhances cell viability significantly, colony-forming invasiveness and ability. Conversely, delivery of villain particular for miR-335 (antagomir-335) to C6 cells outcomes in development police arrest, cell apoptosis, attack dominance and proclaimed regression of astrocytoma xenografts. Additional analysis reveals that miR-335 focuses on disheveled-associated activator of morphogenesis 1(Daam1) at posttranscriptional level. Furthermore, silencing of endogenous Daam1 (siDaam1) could imitate the oncogenic results of miR-335 and invert the development police arrest, proapoptotic and attack dominance results caused by antagomir-335. Particularly, the oncogenic results of miR-335 and siDAAM1 collectively with anti-tumor results of antagomir-335 are also verified in human being astrocytoma U87-MG cells. Summary These results recommend an oncogenic ...
Mitochondrial Lactate Dehydrogenase Is Involved in Oxidative-Energy Metabolism in Human Astrocytoma Cells CCF-STTG1. . Biblioteca virtual para leer y descargar libros, documentos, trabajos y tesis universitarias en PDF. Material universiario, documentación y tareas realizadas por universitarios en nuestra biblioteca. Para descargar gratis y para leer online.
The cyclin-dependent kinase member, Cdk5, is expressed in a variety of cell types, but neuron-specific expression of its activator, p35, is thought to limit its activity to neurons. Here we demonstrate that both Cdk5 and p35 are expressed in the human astrocytoma cell line, U373. Cdk5 and p35 are present in the detergent-insoluble cytoskeletal fraction of this cell line and Cdk5 localizes to filopodia and vinculin-rich regions of cell-matrix contact in lamellopodia. When exposed to a 46(o)C heat shock, U373 cells change shape, lose cell-matrix contacts and show increased levels of apoptosis. To test whether Cdk5 activation might play a role in these events, U373 cells were stably transfected with histidine-tagged or green fluorescent protein-tagged constructs of Cdk5 or a dominant negative mutation, Cdk5T33. Under normal growth conditions, growth characteristics of the stably transfected lines were indistinguishable from untransfected U373 cells and Cdk5 localization was not changed. However, ...
Work in this thesis was primarily involved with the characterisation of four receptors, the turkey and bovine P2Y1, and the human P2Y2 and P2Y4 receptors, transfected into the human astrocytoma cell line, 1321N1. It also describes the preliminary characterisation of two vascular smooth muscle cell types, and the generation of P2Y1-GST fusion proteins for the production of antibodies.;1321N1 cells were found to release nucleotides in response to sheer stress, but this was overcome by adaptation of the stimulation method. 1321N1 cells expressing the four receptors were assayed for PLC activity, and the rank order of agonist potency for each receptor was generally consistent with reports in the literature. Nucleotide interconversion at the surface of 1321N1 cells was also examined indirectly using the ecto-ATPase inhibitor ARL 67156 and hexokinase. Although there was no significant effect of nucleotide breakdown on the agonist concentration-responses, it was found that upstream conversion of ...
Low-grade astrocytomas are a heterogeneous group of intrinsic central nervous system (CNS) neoplasms that share certain similarities in their clinical presentation, radiologic appearance, prognosis, and treatment. The most common intrinsic brain tumor, glioblastoma multiforme, is high grade and malignant.
astrocytoma - MedHelps astrocytoma Center for Information, Symptoms, Resources, Treatments and Tools for astrocytoma. Find astrocytoma information, treatments for astrocytoma and astrocytoma symptoms.
For patient information click here Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1];Associate Editor(s)-in-Chief: Marjan Khan M.B.B.S.[2] Synonyms and Keywords: Spongioblastoma multiforme; glioblastoma; glioblastomas; GBM; GBMs; G.B.M; grade IV astrocytoma; grade IV astrocytomas; astrocytoma, grade IV; undifferentiated glioma; grade IV malignant astrocytoma; grade IV malignant glioma; kernohan grade IV astrocytoma; St. Anne/Mayo astrocytoma grade 4; butterfly glioma ...
Intramedullary mixed signal cervical spinal cord mass. No evidence of hemorrhage. Mild expansile remodeling of the cervical spinal bony canal. The tumor enhances heterogeneously
In the present series, glioma was the most common diagnosis, representing 40.1% of cases (sixty nine patients): 23 (33.8%) were classified as glioblastoma multiforme (WHO IV), 13 (19.1%) as anaplasic astrocytoma (WHO III) and 11 as low grade astrocytomas (10%). Two patients (1.2%) had their lesions classified as probable low grade astrocytoma and one (0.6%) as oligodendroglioma.. The rest of tumors (12.2%) were classified as: lymphomas (7%), metastasis (2.3%), germinomas (1.2%), epidermoid cyst (0.6%) and primitive neuroectoderm tumor (1.2%). Metastasis were originated from pulmonary carcinoma, kidney and colon. Only one case ended in undifferentiated carcinoma as the diagnosis. Two HIV positive patients had B-cell non-Hodgkin lymphomas. From the other 10 HIV negative patients, 5 had the same B-cell non-Hodgkin lymphoma, 1 T-cell lymphoma, 2 high grade non-Hodgkin lymphoma, 1 primary brain lymphoma and 1 a Reed- Steinberg variance of Hodgkins disease.. An inflammatory or infectious process was ...
Progesterone receptors (PR) have been detected in human astrocytomas; however, the expression pattern of PR isoforms in these brain tumors is unknown. Progesterone receptor isoforms expression was studied in 13 biopsies of astrocytomas (6 grade III, and 7 grade IV) from adult Mexican patients by using reverse transcription-polymerase chain reaction and immunohistochemistry. Progesterone receptor expression was observed at mRNA and at protein levels in 66% and 83% of astrocytomas grade III, respectively, whereas 100% of astrocytomas grade IV expressed PR. Almost all PR mRNA content in astrocytomas grades III and IV corresponded to PR-B. The number of immunoreactive cells expressing PR-B was higher than that expressing PR-A in 73% of the cases. Estrogen receptor-á protein was only observed in 33% of astrocytomas grade III, whereas no astrocytomas grade IV expressed it. These data suggest that PR-B is the predominant isoform expressed in human astrocytomas grades III and IV, and that estrogen ...
Adjuvant chemotherapy using DNA-damaging agents has largely failed to make a significant impact on the outcome of patients with malignant astrocytoma. One of the primary mechanisms of resistance to nitrosureas such as CCNU is mediated through O6-methylguanine-DNA methyltrans-ferase (MGMT). This DNA repair enzyme removes the cytotoxic alkyl adducts from O6-guanine, and hence the level of MGMT activity in tumor cells is related to their sensitivity to nitroureas. It has been proposed that functional inactivation of MGMT through hypermethylation of the gene promotor region could be predictive of chemosensitivity. We have previously reported differential sensitivity to CCNU in a panel of 17 short-term cultures derived from malignant astrocytoma. In this study, we determined the methylation status of MGMT using methylation-specific PCR in these 17 cultures. We also assessed the amounts of MGMT mRNA and protein present in each culture using real-time quantitative PCR and immunohistochemistry with a ...
Astrocytic tumors are the most common intracranial neoplasms. Their prognoses correlate with a conventional morphological grading system that suffers from diagnostic subjectivity and hence, inter-observer inconsistency. A molecular marker that provides an objective reference for classification and prognostication of astrocytic tumors would be useful in diagnostic pathology. RhoA, a GTPase protein involved in cell migration and adhesion, has been shown to be upregulated in a variety of human cancers. Based on direct analysis of clinical materials, our study demonstrates increased expression of RhoA in high-grade astrocytomas. This observation may be relevant to astrocytoma biology and the development of potential therapeutics against high-grade astrocytomas. Of more immediate consequence, utilization of this marker may aid in the routine pathological grading (and hence prognostication) of astrocytomas. © 2006 Elsevier Ireland Ltd. All rights reserved ...
In bacterial meningitis, LPS induces production in cerebrospinal fluid of the cytokines IL-1 beta and tumor necrosis factor alpha (TNF alpha), which are the principle mediators of meningeal inflammation. IL-1 beta and TNF alpha induce fever, and elevated temperature may affect cytokine expression. Dexamethasone treatment improves outcome in bacterial meningitis possibly by inhibiting IL-1 beta and TNF alpha. In this report, the effects of elevated temperature and dexamethasone on LPS-stimulated IL-1 beta and TNF alpha mRNA gene expression and protein synthesis were studied in human astrocytoma cell lines and primary cultures of human fetal astrocytes. Cells cultured at 40 degrees C exhibited smaller peaks of IL-1 beta and TNF alpha transcription and protein synthesis compared with cells cultured at 37 degrees C. The addition of dexamethasone before, during, or after exposure of the cells to LPS resulted in temperature-dependent inhibition of IL-1 beta transcription and protein synthesis. The ...
Klironomos, G., Bravou, V., Papachristou, D. J., Gatzounis, G., Varakis, J., Parassi, E., Repanti, M. and Papadaki, H. (2010), Loss of Inhibitor of Growth (ING-4) is Implicated in the Pathogenesis and Progression of Human Astrocytomas. Brain Pathology, 20: 490-497. doi: 10.1111/j.1750-3639.2009.00325.x ...
This never-ending cycle of tests, treatments and time spent recovering from surgeries deprives diagnosed children of their childhood. We have watched our son suffer through this disease for almost 9 years. Most devastating of all, we could not stop the tumor from taking his eyesight.. ...
Protoplasmic astrocytoma is a rare variant of diffuse low-grade astrocytomas with histological and imaging features which overlap with other entities. Until recently they were classified as a subtype of low-grade diffuse astrocytoma, however, i...
A collection of disease information resources and questions answered by our Genetic and Rare Diseases Information Specialists for Cerebral astrocytoma, childhood
Neuroepithelial tumors. Astrocytic tumors. An increased risk of astrocytic tumors has been observed in patients who receive therapeutic radiation therapy for pituitary adenomas, craniopharyngioma, pineal parenchymal tumors, germinoma, and tinea capitis. In addition, children who receive prophylactic radiation therapy of the CNS for acute lymphoblastic leukemia have an increased risk of developing astrocytomas. Recurrent lesions often signal histologic progression to a higher grade; this malignant progression is associated with a cumulative acquisition of multiple genetic alterations. [4] Pilocytic astrocytoma (WHO grade I) is a grossly circumscribed, slow-growing, often cystic tumor that occurs primarily in children and young adults. [5] Histologically, pilocytic astrocytomas are composed of varying proportions of compacted bipolar cells with Rosenthal fibers and loose-textured multipolar cells with microcysts and granular bodies. This tumor is the most common glioma in children and represents ...
Introduction:. Astrocytomas are the most common subtype of glioma, accounting for about 70% of all malignant tumors found in the central nervous system. Genetic alterations in gliomas have been extensively researched, but epigenetic changes are less well investigated. The aim of this study is to analyze genome-wide patterns of DNA methylation in a set of astrocytic tumors to identify aberrantly methylated genes, which could serve as candidates for new diagnostic markers and/or therapeutic targets.. Material & Methods:. DNA methylation was investigated genome-wide by methyl-DNA immunoprecipitation (MeDIP) and hybridization to customized Agilent Human CpG island (250K) oligonucleotide arrays. In total, 18 glioblastoma cell lines, 59 astrocytic tumor samples (4 diffuse astrocytomas WHO grade II, 17 anaplastic astrocytomas grade III and 38 glioblastomas grade IV) and 5 normal whole brain samples were analyzed. Data quality control, normalization and analysis was performed through the arrayQuality ...
Contrast studies -- Coronal post-gadolinium T1-weighted image shows the medial portion of solid component enhancing with contrast material. Note bilateral tonsils sagging into the ...
My husband was diagnosed with what we call a family nightmare brain tumor call Anaplastic Astrocytoma Grade 3 this past year end on October 2012 He had hardly no symtoms just some tingling on his left hand which he thought to be arthritis in his joints and suddenly developed a fever over night mid October we went to the hospital where we were told it was the flu but what we thought to be the flu as quick as it came it returned my husband left home seemingly fine gave me a kiss and went off to work driving through midtown Manhattan he suddenly felt what seem to be a charlie horse pain in his left cuff and promptly parked his plumbing truck vehicle which he drove while his co-worker watched and followed behind him to the side of the vehicle when he calpse to the ground what it look like a stroke was 5 seizures by the time he arrived at New York Presbyterian Cornell ER many seris of test done Blood/Urine Test, Cat Scan, X Ray and finally MRI they found he had a mass in an inoperable location in the ...
Phase 2 trial to explore the efficacy and safety of irinotecan (CPT-11) in patients with recurrent anaplastic astrocytomas (AA), mixed malignant glioma, and oligodendrogliomas (OA). Patients were to be stratified by tumor histology and treated with CPT-11 every 21 days (treatment cycle).. Baseline data (collected ,14 days) was to consist of a neurological/oncological history, neurological examination, height, weight, performance status, Quality Of Life FACT-L questionnaire, laboratory studies to include complete blood count (CBC), differential, platelets, prothrombin time (PT), complete metabolic panel (CMP), Lactose dehydrogenase (LDH), and a pregnancy test, as well as a cranial Computerized Tomography/Magnetic Resonance Imaging (CT/MRI) with and without contrast (to measure or evaluate the size and location of the tumor before treatment).. Administered every 21 days was a dose of irinotecan (CPT-11), zofran/Kytril/Anzemet, decadron, and intravenous (IV) atropine. At each cycle, patient exams ...
Phase 2 trial to explore the efficacy and safety of irinotecan (CPT-11) in patients with recurrent anaplastic astrocytomas (AA), mixed malignant glioma, and oligodendrogliomas (OA). Patients were to be stratified by tumor histology and treated with CPT-11 every 21 days (treatment cycle).. Baseline data (collected ,14 days) was to consist of a neurological/oncological history, neurological examination, height, weight, performance status, Quality Of Life FACT-L questionnaire, laboratory studies to include complete blood count (CBC), differential, platelets, prothrombin time (PT), complete metabolic panel (CMP), Lactose dehydrogenase (LDH), and a pregnancy test, as well as a cranial Computerized Tomography/Magnetic Resonance Imaging (CT/MRI) with and without contrast (to measure or evaluate the size and location of the tumor before treatment).. Administered every 21 days was a dose of irinotecan (CPT-11), zofran/Kytril/Anzemet, decadron, and intravenous (IV) atropine. At each cycle, patient exams ...
Grade 2 to 4 pediatric astrocytomas share histopathologic similarities with their corresponding adult counterparts, and, in general, pathologic examination does not distinguish pediatric and adult tumors of the same malignancy grade. Numerous studies have identified signature genetic mutations in high-grade adult astrocytomas, including the recent TCGA analysis of GBM tumors (4). The TCGA study showed that EGFR, PTEN, and TP53 changes are among the most frequently observed alterations in adult GBM, whereas recent studies using parallel genomic approaches showed that mutations in the IDH1 gene predominate in adult gliomas (5, 16). With the possible exception of TP53 mutation, the frequent genetic alterations seen in adult astrocytomas have been identified at lower frequencies in pediatric astrocytomas (2, 3, 17). This lack of signature genetic mutations in pediatric astrocytomas is unfortunate, as these serve as important reference points with which to test therapeutic hypotheses.. The results of ...
About one-third of brain tumors are diffuse astrocytic tumors associated with dismal prognoses because of their marked capacity to diffusely invade the normal brain parenchyma. Their level of malignancy increases from astrocytomas (World Health Organization/WHO grade II) to anaplastic astrocytomas (WHO grade III) and glioblastoma (WHO grade IV). The human U373 cellular model used in our experiments exhibited biological and histopathological properties characteristic of a malignant astroglioma. The exceptional capacity of isolated astrocytic tumor cells to diffuse from the tumor body into the normal surrounding brain parenchyma is due to two major events, namely, invasion and motility (De Hauwer et al., 1998).. Although no effective treatment exists today against malignant astrocytomas, and because we observed that gastrin is able to significantly modulate the cell growth and motility of human glioblastoma cells (Camby et al., 1996; De Hauwer et al., 1998), we believe that gastrin-based therapy ...
Canada, and more specifically its Brain Tumour Foundation, has decided to fall in line with the Americans again: May is the new Brain Tumour Awareness Month. So much for the Holy Month of October (although I do very much respect the mammary aspect of that month). I shant fountainously spout my bile over the various little nitty-picky problems I have with this example of Manifest Destiny, assuming the spellings of grey and tumour shall not change to the rather appalling gray and tumor, and instead I choose to simply celebrate my "own" tumour day. For according to the Foundations Brain-Tumour-a-Day-in-May schedule, the 18th of May is reserved for Anaplastic Astrocytoma. Very well. It would have been, once upon a time, the 4th of May: Oligoastrocytoma day. Well, grade II no more. Onwards. ...
The relative resistance of malignant glioma to chemotherapy makes the identification of new cytotoxic drugs critically important. The use of short-term cultures derived from these tumors to screen drugs at doses that can be attained within human intracranial tumors provides a model system that should be capable of identifying effective drugs suitable for clinical evaluation. The sensitivity of a panel of short-term cultures derived from 22 malignant astrocytoma and four malignant oligodendroglioma was assessed to aziridinylbenzoquinone (AZQ), etoposide and doxorubicin (DOX) using a [(35)S] methione uptake assay. The ID(50) of each culture was compared to the levels of drug which could be achieved in the tumor using standard doses. There was marked heterogeneity between cultures in response to each drug. Whilst there was no evidence that cultures derived from grade III astrocytoma were more sensitive to any of the drugs than cultures derived from grade IV astrocytoma, cultures derived from ...
Astrocytic tumors are the most common malignancies of the central nervous system, accounting for more than 60% of all primary brain tumors. The prognosis for high grade astrocytoma patients is dismal and there is no curative treatment, today. A molecular hallmark of astrocytic tumors is dysregulated receptor tyrosine kinase signaling, especially of the epidermal growth factor receptor (EGFR, ErbB1). The aim of the present thesis was to identify endogenous human proteins that downregulate the function of the ErbB1 receptor. We identified a human gene family, the leucine-rich repeats and immunoglobulin-like domains family (LRIG), consisting of LRIG1, LRIG2 and LRIG3, which might fulfill this criterion.. Two candidates were identified, LRIG1 and LRIG2, which genes were localized to regions frequently deleted in human cancers, chromosome bands 3p14 and 1p13, respectively. LRIG1 and LRIG2 mRNA were expressed in all tissues analyzed, with high expression in brain and other organs. The LRIG mRNA were ...
Astrocytic tumors are the most common malignancies of the central nervous system, accounting for more than 60% of all primary brain tumors. The prognosis for high grade astrocytoma patients is dismal and there is no curative treatment, today. A molecular hallmark of astrocytic tumors is dysregulated receptor tyrosine kinase signaling, especially of the epidermal growth factor receptor (EGFR, ErbB1). The aim of the present thesis was to identify endogenous human proteins that downregulate the function of the ErbB1 receptor. We identified a human gene family, the leucine-rich repeats and immunoglobulin-like domains family (LRIG), consisting of LRIG1, LRIG2 and LRIG3, which might fulfill this criterion.. Two candidates were identified, LRIG1 and LRIG2, which genes were localized to regions frequently deleted in human cancers, chromosome bands 3p14 and 1p13, respectively. LRIG1 and LRIG2 mRNA were expressed in all tissues analyzed, with high expression in brain and other organs. The LRIG mRNA were ...
SUAREZ, Julio César et al. Gliomas cerebrales de bajo grado en el adulto. Rev. argent. neurocir. [online]. 2008, vol.22, n.1. ISSN 1850-1532.. Objective. Gliomas reviewed in this article are grade II tumors according to the World Health Organization (WHO), that include: fibrillary and protoplasmic astrocytomas, oligodendrogliomas and oligoastrocytomas or mix tumors (1,2,3).Low grade astrocytomas constitute 15% of brain tumors in adults, while low grade oligodendrogliomas represent 4% (2,4). We present our experience with this type of tumor operated on between January 1972 and December 2006. Material and Method. The clinical reports of 25 patients with this type of tumor were analyzed, 15 women and 10 men, which represent 15,6% of hemispheric brain gliomas in adults in our series. Results. Fifteen were fibrillary astrocytomas, 8 oligodendrogliomas and 2 oligoastrocytomas. Treatment depended on tumor localization and size. Surgery and radiotherapy were the therapeutic modalities most frequently ...
TY - JOUR. T1 - Involvement of aquaporin in thromboxane A2 receptor-mediated, G12/13/RhoA/NHE-sensitive cell swelling in 1321N1 human astrocytoma cells. AU - Saito, Masaki. AU - Tanaka, Hiroyuki. AU - Sasaki, Masako. AU - Kurose, Hitoshi. AU - Nakahata, Norimichi. PY - 2010/1/1. Y1 - 2010/1/1. N2 - The physiological role of the thromboxane A2 (TXA2) receptor expressed on glial cells remains unclear. We previously reported that 1321N1 human astrocytoma cells pretreated with dibutyryl cyclic AMP (dbcAMP) became swollen in response to U46619, a TXA2 analogue. In the present study, we examined the detailed mechanisms of TXA2 receptor-mediated cell swelling in 1321N1 cells. The cell swelling caused by U46619 was suppressed by expression of p115-RGS, an inhibitory peptide of Gα12/13 pathway and C3 toxin, an inhibitory protein for RhoA. The swelling was also inhibited by treatment with Y27632, a Rho kinase inhibitor and 5-(ethyl-N-isopropyl)amiloride (EIPA), a Na+/H+-exchanger inhibitor. Furthermore, ...
We have generated a transgenic mouse model for astrocytoma by expressing the v-src kinase under control of the glial fibrillary acidic protein (GFAP) gene regulatory elements in astrocytes. Abnormal astrogliosis was observed in all transgenic animals already at 2 weeks postnatally, frequently followed by the development of dysplastic changes. Later, small proliferative foci arose, and overt astrocytoma developed in the brain and spinal cord in 14.4% of mice after a follow up time of 65 weeks. While early lesions were histologically consistent with low-grade astrocytoma, at later stages most tumors were highly mitotic and frankly malignant. Vascular endothelial growth factor (VEGF) was expressed by tumor cells already at early stages, suggesting induction by v-src, and it was most pronounced in pseudopalisading cells surrounding necrotic areas, implying additional upregulation by hypoxia. In larger lesions, mitotic activity and expression of flk-1, the cognate receptor of VEGF were induced in ...
Inquire for Anaplastic Astrocytoma Drug Market Competitive Analysis, Trends and Forecast till 2022, with free sample copy of the report.
Pricola Fehnel et al., report the use of urinary biomarkers as a novel, noninvasive technique to detect juvenile pilocytic astrocytomas (JPAs), capable of distinguishing JPAs from other CNS diseases, including other brain tumors. Preliminary screening of an array of tumors implicated proteases (including matrix metalloproteinases [MMPs]) and their inhibitors (tissue inhibitors of metalloproteinase [TIMPs]) as well as growth factors (including basic fibroblast growth factor [bFGF]) as candidate biomarkers. These data led the authors to hypothesize that tissue inhibitor of metalloproteinase 3 (TIMP3) and bFGF would represent high-probability candidates as JPA-specific biomarkers. Urine was collected from 107 patients, which included children with JPA (n = 21), medulloblastoma (n = 17), glioblastoma (n = 9), arteriovenous malformations (n = 25), moyamoya (n = 14), and age- and sex-matched controls (n = 21). Biomarker levels were quantified with enzyme-linked immunosorbent assay, tumor tissue ...
Brain tumor" is a term the majority of us are familiar with, and most of us hearing it feel similarly anxious. A brain tumor originates … ...
Diffuse astrocytomas grow slowly, but they often spread into nearby tissues. Some of them progress to a higher grade. They occur most often in young adults.
Summary A series of 42 cases of monstrocellular brain tumour (MBT) who received surgery over a 34 year period is reviewed with the aim of gaining more understanding of the biology of this oncotype. A case of benign pleomorphic xanthoastrocytoma was identified among the cases and is discussed in... mehr ...
ENCODES a protein that exhibits DNA binding (ortholog); DNA-binding transcription factor activity, RNA polymerase II-specific (ortholog); metal ion binding (ortholog); INVOLVED IN dorsal/ventral pattern formation (ortholog); embryonic limb morphogenesis (ortholog); proximal/distal pattern formation (ortholog); ASSOCIATED WITH pleomorphic xanthoastrocytoma (ortholog); FOUND IN nuclear chromatin (ortholog); nucleus (ortholog)
Pilocytic astrocytoma (PA) is the most common glioma in the pediatric population. PAs can exhibit variable behavior that does not always correlate with location. Although oncogenic rearrangements of t
Previously, we have used large-scale gene expression analysis to characterize primary and secondary glioblastomas. By comparing with low-grade astrocytoma, we have identified a series of glioblastoma-associated genes that could distinguish primary glioblastomas from the secondary glioblastomas (14). The comparison with lower-grade astrocytomas was done to attempt selecting for genes, which are specific to the end malignant transformation into the highly invasive glioblastomas. Secondary glioblastoma-associated genes primarily include mitotic cell cycle components, suggesting loss of function in prominent cell cycle regulators, whereas primary glioblastoma-associated genes highlight genes expressed in mesenchyme-derived tissues and stromal response, suggesting the augmentation of extracellular signaling operating the malignancy. To identify genes potentially link to cellular properties and tumorigenesis of primary glioblastoma, in this study, we compared primary glioblastoma with normal brain ...
Patients may first come to medical attention for LGA because of new-onset seizures. This is likely to be the case for tumors of cerebral hemispheric location, either PA, FA, or PXA. Tumor-provoked seizures are often controlled initially with antiepileptic medications, but surgical resection is usually the treatment of choice to improve seizure control, psychosocial and intellectual development, and daily function.. Depending on tumor location, electrophysiologic and semiologic data, surgical options range from lesionectomy to resection of neighboring structures (e.g., portions of the mesial temporal lobe). Patients often wean slowly from antiepileptic medications after resection.. In patients with visual loss from an optic pathway LGA, surgical resection may be indicated for proptosis or exposure keratitis. Occasionally, tumor debulking with or without cerebrospinal fluid diversion is required to alleviate hydrocephalus or diencephalic symptoms.. In contrast to LGA at other sites, extent of ...
Cardiology news, research and treatment articles offering cardiology healthcare professionals cardiology information and resources to keep them informed.
Looking for information on Benign Astrocytoma? Medigest has all you need to know about Benign Astrocytoma - Symptoms and Signs, Causes, Treatments and definition
TY - JOUR. T1 - cIMPACT-NOW update 3. T2 - recommended diagnostic criteria for "Diffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma, WHO grade IV". AU - Brat, Daniel J.. AU - Aldape, Kenneth. AU - Colman, Howard. AU - Holland, Eric C.. AU - Louis, David N.. AU - Jenkins, Robert Brian. AU - Kleinschmidt-DeMasters, B. K.. AU - Perry, Arie. AU - Reifenberger, Guido. AU - Stupp, Roger. AU - von Deimling, Andreas. AU - Weller, Michael. PY - 2018/1/1. Y1 - 2018/1/1. UR - http://www.scopus.com/inward/record.url?scp=85053870232&partnerID=8YFLogxK. UR - http://www.scopus.com/inward/citedby.url?scp=85053870232&partnerID=8YFLogxK. U2 - 10.1007/s00401-018-1913-0. DO - 10.1007/s00401-018-1913-0. M3 - Article. C2 - 30259105. AN - SCOPUS:85053870232. JO - Acta Neuropathologica. JF - Acta Neuropathologica. SN - 0001-6322. ER - ...
Selected genes exclusively observed in PA I Considering genes that were exclusively differentially expressed in PA I, we observed several under- (e.g. EN2, EOMES, MEIS1, NEUROD1, ZIC1, ZIC2, ZIC3, ZIC4) and overexpressed (e.g. EGR1, EGR3, OLIG1) TFs involved in brain development. For example, EOMES is involved in neuron division and/or migration [52]. Additionally, three known chromatin remodelers (SUV420H1, SUV420H2, SUZ12) were underexpressed in PA I. In accordance with a recent study [53], ATRX, a biomarker of adult astrocytomas, was underexpressed in PA I. In contrast to AS III and GBM IV, HIF1AN was strongly overexpressed in PA I. Further, CDKN2B, a tumor suppressor for which overexpression has been reported to inhibit cell proliferation and to cause senescence of glioma cells with intact RB pathway [54], was overexpressed. OLIG2, which has been reported to show increased expression in PA I and high-grade gliomas [55], was overexpressed. NRTK2, which has been reported to be highly expressed ...
The patient went on to have debulking. Histology MICROSCOPIC DESCRIPTION: All the sections show a densely cellular astrocytic tumour. The astrocytes form sheets. Most of these cells are gemistocytes with enlarged hyperchromatic nuclei and mode...
The tumor arises from star-shaped glial cells called astrocytes. In adults, astrocytomas most often arise in the cerebrum. In children, they occur in the brain stem, the cerebrum, and the cerebellum. A grade III astrocytoma is sometimes called an anaplastic astrocytoma. A grade IV astrocytoma is usually called a glioblastoma multiforme ...
If someone has had chemotherapy treatments for the above mentioned (brain) tumor, does it mean he/she has cancer? I thought chemo is only to treat cancer cells, however Ive read an article that it,...
We are a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for us to earn fees by linking to Amazon.com and affiliated sites.. Any of the sites under Claire Bullimore or Aunty M Brain Tumours is not intended to provide and does not constitute medical, legal, or other professional advice. The content on Aunty M Brain Tumours is designed to support, not replace, medical or psychiatric treatment.. ...
The use of mushrooms contributes to human nutrition by providing low lipid content of lipids and high dietary fiber content, as well as significant content of o...
PubMed comprises more than 30 million citations for biomedical literature from MEDLINE, life science journals, and online books. Citations may include links to full-text content from PubMed Central and publisher web sites.
... MUHAMED IBRAHEEM JALAL AL-MASRY 26 YEARS SEVERE PARAPARESIS DUE TO EXOPHYTIC LOW-GRADE ASTROCYTOMA OF THE SPINAL CORD WITH ANTERIOR EXTRAMEDULLARY CYST.
So my friend told me not 30 minutes ago that her sister has a level 4 astrocytoma. I looked it up and Wikipedia, its hard to understand it like, technically, but I did learn how dangerous it is. So I guess my question is, does anyone know anything about astrocytomas? Layman terms, please. To make the thread more relevant, have you or any relatives/friends had cancer before? What kind was it? What was it like? PS: Ive been wondering, how does cancer kill people? Im guessing there are
Slow growing cystic tumor that occurs primarily in children and young adults. Location of tumors is in the optic nerve, optic hypothalamus, thalamus and basal ganglia, cerebral hemispheres, cerebellum, and brain stem. Associated with Neurofibromatosis Type 1 (NF1). Rarely fatal disease.
TY - CHAP. T1 - LASSO method in variable selection for right-censored time-to-event data with application to astrocytoma brain tumor and chronic myelogenous leukemia. AU - Yu, Lili. AU - Pearl, Dennis Keith. PY - 2009/1/1. Y1 - 2009/1/1. N2 - We propose models of potential relationships in time-to-event data and we infer whether these associations occur based on the support of the available data. Our inferences are only as good as the models that we use to define these associations of interest. Cox proportional hazard model [1,2] is the most popular model used in survival analysis due to the computational simplicity of the inference methods and wellestablished asymptotic properties of the partial likelihood. However, the proportional hazards assumption is not always true since the hazard ratio for real data often converges to 1 as time increases.. AB - We propose models of potential relationships in time-to-event data and we infer whether these associations occur based on the support of the ...
Baggiolini M, Dahinden CA. CC chemokines in allergic inflammation. Immunol. Today (1994) 15:127-133.. Baggiolini M, Dewald B, Moser B. Interleukin-8 and related chemotactic cytokines-CXC and CC chemokines. Adv. Immunol. (1994) 55:97-179.. Barnes DA, Huston M, Holmes R, Benveniste EN, Yong VW, Scholz P, Perez HD. Induction of RANTES expression by astrocytes and astrocytoma cell lines. J. Neuroimmunol. (1996) 71: 207-214.. Beck LA, Dalke S, Leiferman KM, Bickel CA, Hamilton R, Rosen H, Bochner BS, Schleimer RP. Cutaneous injection of RANTES causes eosinophil recruitment: comparison of nonallergic and allergic human subjects. J Immunol. (1997) 159:2962-2972.. Bevilacqua MP, Gimbrone MA Jr. Inducible endothelial functions in inflammation and coagulation. Semin Thromb Hemost. (1987) 13:425-433.. Black RA, Rauch CT, Kozlosky CJ, Peschon JJ, Slack JL, Wolfson MF, Castner BJ, Stocking KL, Reddy P, Srinivasan S, Nelson N, Boiani N, Schooley KA, Gerhart M, Davis R, Fitzner, Johnson RS, Paxton RJ, March ...
My youngest son has a recurring astrocytoma.  He has undergone 2 resections in two years.  It appears the tumor has reoccurred.  He doesnt want...
astrocytoma treatment in Israel is carried out in the clinic Assuta best neurosurgeons. We provide the best treatment plan based on your diagnosis.
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-ener
... AHMAD FAYSAL OEDEH 38 YEARS MALIGNANT HIGH GRADE ASTROCYTOMA LEFT TEMPORO-FRONTAL LOBES WITH IMPENDING CONNING.
Expression of SphK1, but not SphK2, in human astrocytoma grade 4 (glioblastoma multiforme) tissue correlated with short patient survival ...
Hi all. This is my first post. I am a survivor (going on six years) of an anaplastic astrocytoma grade III in my left frontal lobe. Temodar failed for me...
PubMed comprises more than 30 million citations for biomedical literature from MEDLINE, life science journals, and online books. Citations may include links to full-text content from PubMed Central and publisher web sites.
Diagnosis, Cell, Survival, Genome, Tumors, Anaplastic Astrocytoma, Animal, Animal Models, Astrocytoma, Cell Lines, Control Group, Drugs, Glioblastoma, Glioblastoma Multiforme, Glioma, Gliomas, Hip, Hip Fractures, Logistic Regression, Odds Ratio
In this study, we have used a unique approach to screen our cancer microarray database to identify potential secreted biomarkers. In the first step, we pulled out expression data of all the genes whose protein products localized either in the plasma membrane or were secreted. Using SAM, we identified GBM-specific serum markers and subsequently validated many of them. Some of the genes identified in this screen, such as CHI3L, IGFBP2, and VEGFA, have been previously reported as GBM-specific serum markers with prognostic value (15-18). In our study, we could also show the GBM-specific expression of the transcripts of these genes by RT-qPCR (data not shown). These previous findings from others and the real-time RT-qPCR validation from our study provide support to our methodology of detecting serum biomarkers.. We have also identified few novel genes that are specifically regulated in GBM. CALU is a novel gene found upregulated specifically in GBM but not in low-grade astrocytomas and ...
Canada, and more specifically its Brain Tumour Foundation, has decided to fall in line with the Americans again: May is the new Brain Tumour Awareness Month. So much for the Holy Month of October (although I do very much respect the mammary aspect of that month). I shant fountainously spout my bile over the various little nitty-picky problems I have with this example of Manifest Destiny, assuming the spellings of grey and tumour shall not change to the rather appalling gray and tumor, and instead I choose to simply celebrate my "own" tumour day. For according to the Foundations Brain-Tumour-a-Day-in-May schedule, the 18th of May is reserved for Anaplastic Astrocytoma. Very well. It would have been, once upon a time, the 4th of May: Oligoastrocytoma day. Well, grade II no more. Onwards. ...
Activation of the MAPK pathway is well established as the oncogenic driver of the pilocytic astrocytoma. It is most frequently caused by KIAA1549:BRAF fusions, and leads to oncogene induced senescence (OIS). OIS is thought to be a major reason for growth arrest of PA cells in vitro and in vivo, preventing establishment of PA cultures 2). Mitogen-activated protein kinases (MAPK) are protein kinases that are specific to the amino acids serine, threonine, and tyrosine. MAPKs belong to the CMGC (CDK/MAPK/GSK3/CLK) kinase group. MAPKs are involved in directing cellular responses to a diverse array of stimuli, such as mitogens, osmotic stress, heat shock and proinflammatory cytokines. They regulate cell functions including proliferation, gene expression, differentiation, mitosis, cell survival, and apoptosis. MAP kinases are found in eukaryotes only, but they are fairly diverse and encountered in all animals, fungi and plants, and even in an array of unicellular eukaryotes. The closest relatives of ...
Helm, M; Müller, W; Schaarschmidt, D; Grimm, F; Deplazes, P (2013). Allopurinol-Therapie bei importierten Hunden mit Leishmaniose ausserhalb des Endemiegebietes. Schweizer Archiv für Tierheilkunde, 155(10):559-567.. Wiestler, B; Claus, R; Hartlieb, S A; Schliesser, M G; Weiss, E K; Hielscher, T; Platten, M; Dittmann, L M; Meisner, C; Felsberg, J; Happold, C; Simon, M; Nikkhah, G; Papsdorf, K; Steinbach, J P; Sabel, M; Grimm, C; Weichenhan, D; Tews, B; Reifenberger, G; Capper, D; Müller, W; Plass, C; Weller, M; Wick, W (2013). Malignant astrocytomas of elderly patients lack favorable molecular markers: an analysis of the NOA-08 study collective. Neuro-Oncology, 15(8):1017-1026.. Hatt, Jean-Michel; Sandmeier, P; Müller, W (2011). Galaktomannan-Untersuchungen zum Nachweis von Aspergillosen intra vitam bei Vögeln - Möglichkeiten und Grenzen. In: 2. DVG-Tagung über Vogel- und Reptilienkrankheiten, Hannover, 16 September 2011 - 18 September 2011, 146-150.. Müller, W; Türker, C (2011). Data ...
In 2007, brain cancer survivor Christine Butterfield added two new words to her vocabulary. -- Anaplastic astrocytoma. Learn more about the brain cancer treatments available at MD Anderson's Brain and Spine Center.
Brain tumor" is a term the majority of us are familiar with, and most of us hearing it feel similarly anxious. A brain tumor originates … ...
You can read my posts on surgery to read about surgery in posts written by me during my stays in the hospital and those updated after the fact to fill in all the holes. Following surgery and the discovery that my brain tumor was a Grade Three Anaplastic Astrocytoma, I went into radiation. This was not an easy decision but you can read about it and my decision process in radiation. I did begin having seizures in 2008 and issues with Hydrocephalus/regrowth in 2010/2011 and then chemo in 2011 where I am cuurrently receiving Avastin and the steroid Decradon ...
It was a year ago last month that my nephew suffered the first of many headaches, which, after much persistence from my brother, landed James in St. Louis Childrens Hospital after the discovery of a large tumor in his cervical spine, later determined to be an aggressive anaplastic astrocytoma, which subsequently spread to his brain.. Over the past year Ive made multiple trips back to the Midwest, always flying in and out of St. Louis, a short train ride to the hospital, so last month, when I made travel plans, there was no indication I shouldnt do the same.. A few days after I arrived we were devastated to learn that, after leaving no stone unturned, there was nothing more the doctors could do for James. Despite every effort, the aggressive cancer would inevitably prevail. Knowing that there hadnt been a single "positive outcome" using the cancer drug the oncologists recommended, James parents chose to bring their son home where he could be surrounded by love, familiar settings and, freed ...
It was a year ago last month that my nephew suffered the first of many headaches, which, after much persistence from my brother, landed James in St. Louis Childrens Hospital after the discovery of a large tumor in his cervical spine, later determined to be an aggressive anaplastic astrocytoma, which subsequently spread to his brain.. Over the past year Ive made multiple trips back to the Midwest, always flying in and out of St. Louis, a short train ride to the hospital, so last month, when I made travel plans, there was no indication I shouldnt do the same.. A few days after I arrived we were devastated to learn that, after leaving no stone unturned, there was nothing more the doctors could do for James. Despite every effort, the aggressive cancer would inevitably prevail. Knowing that there hadnt been a single "positive outcome" using the cancer drug the oncologists recommended, James parents chose to bring their son home where he could be surrounded by love, familiar settings and, freed ...
Permanent pathology of cerebellar anaplastic astrocytoma. (a and b) The low-power image displays hypercellularity of neoplastic cells, (c) The high-power image
JaDiamond Williams was diagnosed with Anaplastic Astrocytoma in February 2011. The cancer has robbed the joyful Spartanburg resident of her ability to stand or walk on her own but it has not been able to steal her spirit or determination.. JaDiamond has faced many challenges head on and won and at The Children Security Blankets Camp Victory this year she wasnt about to let a four-hoofed animal with a long mane get the best of her. With the help of volunteers from CSB and Hope Remains Ranch, the brave girl conquered yet another challenge with a sparkle in her eye …she mounted a horse and went for her first ride!. "As I watched JaDiamond get on that horse it brought tears to my eyes," said CSB Executive Director Laura Allen. "To see the effort of the volunteers working with that young lady and to see her accomplish and overcome obstacles was just amazing. She is a young lady that I have so much admiration and respect for.". CSB began partnering with JaDiamond and her family in October of 2011. ...
Improving the grading accuracy of astrocytic neoplasms non-invasively by combining timing information with cerebral blood flow: A multi-inversion-time arterial-spin-labeling magnetic resonance ...
Learn more about Childhood Astrocytomas Treatment (PDQ®) (Patients) from the National Cancer Institute at Siteman Cancer Center.
(20-07-2017 04:15 PM)GirlyMan Wrote: Of the estimated 17,000 primary brain tumors diagnosed in the US each year, approximately 60% are gliomas. Glioblastoma (GB), or grade IV astrocytoma, is the most
Astrocytes are like many little clocks, mess up the times and it can change your genes. I was diagnosed with an astrocytoma so this information is gold ...
Hi Jamie. I have just typed all this and it hasnt worked... try again... I am a friend of Ratty as we call him, just married to Georges aunt. My brother Charlie got a malignant grade 4 astrocytoma aged 15 and was given 3 weeks to live. This was 1985. Cutting a story short, he is still here and the doctors say Charlie we cant understand why you are still here. He was given a biopsy (all they could do, very rare positioning of tumour, they had seen 9 only like it) and it has seemed to be in remission ever since. Btw I took him skiing in Zermatt a year or two after the operation. As you can imagine we have done a lot of thinking over 30 years. What I have drawn from it is that the treatment in the 80s was very basic and is improving exponentially, compared to now and that Charlie has paved the way for anyone else getting a tumour. Our American cousin Rob is a doctor in the US researching just this coincidentally. I asked him to send me his papers and couldnt understand a word. He says they ...
self*care is the keenly awaited debut EP by Sega Bodega, a none-more-hyped producer whos already racked up credits for Quay Dash and Shygirl, and
Background: Tuberous sclerosis (TSC) is inherited as an autosomal dominant disease, characterized by skin lesion and tubers in vital organs, especially brain in three categories including subependymal nodules, cortical tubers and subependymal giant cell astrocytoma. Subependymal giant cell astrocytoma (SEGA) is an indolent neoplasm which usually arises at the cauda thalamic groove near foramen monro, although it occurs usually in the clinical settings of TSC, a few number of SEGA has been reported without such history. Its morphology with special cytoarchitecture could be mistaken with other glial brain tumors with similar morphology. Therefore, investigating new markers for differentiating SEGA from other mimickers seems logical rather than other glioneural immunohistochemical markers introduced before. Case: We investigated CD99 expression in SEGA as an adjunctive marker for diagnostic purposes. Five reported cases of SEGA were studied and all of them showed CD99 expression besides usual glioneural
There are considerable efforts to identify naturally occurring substances as new drugs in cancer therapy. Many components of medicinal plants have been identified that possess substantial anticancerous properties. This prompted us to investigate the effect of Scrophularia striata (an Iranian species belonging to the Scrophulariace family) extract on the growth of astrocyte cancer cell line (1321). The 1321 cell line were seeded in 96-well culture plates in the presence and absence of various concentrations of either leaf and seed filtered and unfiltered extract of Scrophularia striata to determine their probable anticancer effects in comparison with etoposide (chemical anticancer reagent). filtered leaf extract of S. Striata showed strong anticancer effect on 1321cell line as compared to control group (cells not exposed to extracts), and even the group (adenocarcinoma gastric cell line) exposed to etoposide. Unlike the leaf extract, the seed extract activated cell proliferation in all experiments. Flow
Histopathologic grading of astrocytic tumors based on current WHO criteria offers a valuable but simplified representation of oncologic reality and is often insufficient to predict clinical outcome. In this study, we report a new astrocytic tumor microarray gene expression data set (n = 65). We have used a simple artificial neural network algorithm to address grading of human astrocytic tumors, derive specific transcriptional signatures from histopathologic subtypes of astrocytic tumors, and asses whether these molecular signatures define survival prognostic subclasses. Fifty-nine classifier genes were identified and found to fall within three distinct functional classes, that is, angiogenesis, cell differentiation, and lower-grade astrocytic tumor discrimination. These gene classes were found to characterize three molecular tumor subtypes denoted ANGIO, INTER, and LOWER. Grading of samples using these subtypes agreed with prior histopathologic grading for both our data set (96.15%) and an ...
Two related drugs have been shown to shrink or stabilize supependymal giant cell tumors: rapamycin and everolimus. These both belong to the mTOR inhibitor class of immunosuppressants, and are both contraindicated in patients with severe infections. Rapamycin showed efficacy in five cases of SEGA in TSC patients, shrinking their tumor volumes by an average of 65%. However, after the drug was stopped, the tumors regrew. Everolimus, which has a similar structure as rapamycin, but with slightly increased bioavailability and shorter half-life, was studied in 28 patients with SEGA. There was a significant reduction in SEGA size in 75% of the patients, and a mild improvement in their seizures. Everolimus was approved for the treatment of SEGA by the US Food and Drug Administration (FDA) in October, 2010.[1] ...
You need to be signed in to access email alerts. If you have an account log in with your user name and password. If you dont have an account you can just enter your email address in the email box below ...
Fluorescence-guided resection with 5-aminolevulinic acid has been shown to be useful in the resection of certain brain tumors other than high grade gliomas, facilitating the intraoperative differentiation of neoplastic tissue. The technique enables the surgeon to ensure that no tumor fragments remain, thereby achieving higher rates of complete resection.. Tihan first described pilomyxoid astrocytomas in 1999. They are currently classified as grade II astrocytoma according to the WHO classification system and, because of their tendency to recur and their dissemination through the cerebrospinal fluid pathways, they are considered to be more aggressive than pilocytic astrocytoma. As a result, management of these tumors must be more aggressive, always aiming for complete macroscopic resection whenever possible.. In this article, we present a case of pilomyxoid astrocytoma of the third ventricle in which the use of fluorescence-guided resection with 5-ALA facilitated complete resection. Imaging tests ...
Optic Nerve Glioma: Optic nerve glioma is a type of juvenile pilocytic astrocytoma (Grade 1 astrocytoma), which occurs more commonly in children & young adults.
Intracranial meningioma and glioma collision tumors are relatively uncommon and are even more rarely located within the ventricles. Here, we report a case of a patient with an intraventricular meningioma and astrocytoma collision tumor. A 39-year-old man previously underwent excision of an astrocytoma in the triangle area of the lateral ventricle and exhibited good post-surgery recovery. The astrocytoma recurred in situ six years after the surgery, and the case was complicated by a malignant meningioma. The patient recovered well after surgery to treat the recurrence and was administered radiotherapy after discharge. In addition to reporting on this case, we conducted a literature review of collision tumors; based on this review, we propose several hypotheses regarding the formation of collision tumors. We conclude that a possible cause of the collision tumor formation between the intracranial meningioma and the astrocytoma was the recurrence of an astrocytoma-induced malignancy of the arachnoid cells
immune Uncategorized Rabbit Polyclonal to Integrin beta1, Tariquidar Oligodendroglial tumors form a definite subgroup of gliomas, seen as a an improved response to treatment and long term overall survival. marks ICIV). Gliomas exhibiting oligodendroglial features consist of oligodendrogliomas (WHO quality II) and anaplastic oligodendrogliomas (WHO quality III) aswell as oligoastrocytomas (WHO quality II), anaplastic oligoastrocytomas (WHO quality III) and glioblastomas with an oligodendroglial component (GBMO, WHO quality IV) [1]. Oligodendroglial tumors take into account 15-20% of most gliomas [2,3]. The recognition from the genes targeted by full 1p/19q co-deletion, a quality of oligodendrogliomas, is a long-standing Tariquidar search. Combined lack of entire chromosome hands 1p and 19q may be the most frequently recognized hereditary imbalance in oligodendroglial tumors, happening in 60-90% of oligodendrogliomas and 30-50% of oligoastrocytomas while they may be rarely within GBMO [4-6]. The ...
It is often assumed that a parenchymal brain lesion which shows no contrast enhancement on magnetic resonance imaging(MRI) is a"low-grade tumor". We investigated a series of 20 patients with nonenhancing cerebral gliomas ; all underwent stereotactic biopsy or open resection, and histological diagnoses were astrocytoma(n=7), anaplastic astrocytoma(n=7), oligodendroglioma(n=5), and ganglioglioma(n=1). Before surgery, 11 patients underwent [18F] fluorodeoxyglucose positron emission tomography(FDG-PET), and this showed hypermetabolic features in two of four patients with anaplastic astrocytomas and in one of seven with astrocytomas or oligodendrogliomas. Among 17 patients, the mean Ki-67 labeling index was 4.4+/-4.3(range : 0.1-16.7), and the standard error was 1.04. These results indicate that in cerebral gliomas, the enhancing pattern seen on MRI cannot predict the degree of malignancy, and we suggest that even if imaging is consistent with "low-grade glioma", histological verification and close ...
TY - JOUR. T1 - Visionary approach for the treatment of brain tumors. AU - Yoshimoto, Koji. AU - Kada, Akiko. AU - Hatae, Ryusuke. AU - Murata, Hideki. AU - Akagi, Yojiro. AU - Nishimura, Kunihiro. AU - Mizoguchi, Masahiro. AU - Iihara, Koji. PY - 2015/10/25. Y1 - 2015/10/25. N2 - To investigate patient background and current trends in the treatment of brain tumor patients, we analyzed a patient dataset using the Diagnosis Procedure Combination(DPC) database. The DPC data of all inpatients treated between April 2013 and March 2014 in the 327 core and branch hospitals enrolled in the Japan Neurosurgical Society training program were collected. Using ICD-10 code, we could extract 6,142 primary malignant brain tumor patients, 2,538 secondary malignant brain tumor patients, 2,043 pituitary tumor patients, 3,854 meningioma patients, and 5,666 other benign brain tumor patients from amongst a total of 501,609 patients. In this study, we focused on the primary and secondary malignant brain tumor ...
TY - JOUR. T1 - Analysis of NADP+-dependent isocitrate dehydrogenase-1/2 gene mutations in pediatric brain tumors. T2 - Report of a secondary anaplastic astrocytoma carrying the IDH1 mutation. AU - Mascelli, Samantha. AU - Raso, Alessandro. AU - Biassoni, Roberto. AU - Severino, Mariasavina. AU - Sak, Katrin. AU - Joost, Kairit. AU - Milanaccio, Claudia. AU - Barra, Salvina. AU - Grillo-Ruggieri, Filippo. AU - Vanni, Irene. AU - Consales, Alessandro. AU - Cama, Armando. AU - Capra, Valeria. AU - Nozza, Paolo. AU - Garrè, Maria Luisa. PY - 2012/9. Y1 - 2012/9. N2 - Somatic mutations of the isocitrate dehydrogenase-1 gene (IDH1), most commonly resulting in replacement of arginine at position 132 by histidine (p.R132H), have been reported for WHO grade II and III diffuse gliomas and secondary glioblastomas. We investigated IDH1/2 mutations in a retrospective series of 165 pediatric brain tumors, including atypical teratoid/rhabdoid tumors (AT/RT) and choroid plexus tumors, which had not previously ...
Conditions: Anaplastic Astrocytoma; Glioblastoma; Giant Cell Glioblastoma; Gliosarcoma; Anaplastic Oligodendroglioma; Anaplastic Oligoastrocytoma; Anaplastic Ependymoma; Choroid Plexus Carcinoma; Anaplastic Ganglioglioma; Pineal Parenchymal Tumor; Pineoblastoma; Medulloblastoma; PNET; Rhabdoid Tumor; Perineurioma; MPNST; Malignant Meningloma; Anaplastic ...

astrocytoma - Postsastrocytoma - Posts

Treatments and Tools for astrocytoma. Find astrocytoma information, treatments for astrocytoma and astrocytoma symptoms. ... astrocytoma - MedHelps astrocytoma Center for Information, Symptoms, Resources, ... Posts on astrocytoma. 5x5cm Possible astrocytoma in my childs head - Brain/Pituitary Tumors Community ... Is this an astrocytoma at the tip of the cerebellar tonsils? - Chiari Malformation Community ...
more infohttp://www.medhelp.org/tags/show/1003/astrocytoma?section=subjects

Astrocytoma - Overview - Mayo ClinicAstrocytoma - Overview - Mayo Clinic

Astrocytoma - Overview covers diagnosis and treatment for this type of glioma brain tumor, including surgery, chemotherapy and ... Astrocytoma. Astrocytoma. Astrocytoma is a type of cancer that can occur in the brain or spinal cord. It begins in cells called ... Astrocytoma is a type of cancer that can form in the brain or spinal cord. Astrocytoma begins in cells called astrocytes that ... Astrocytoma treatments include:. *. Surgery to remove the astrocytoma. Your brain surgeon (neursurgeon) will work to remove as ...
more infohttps://www.mayoclinic.org/diseases-conditions/astrocytoma/cdc-20350132?mc_id=bing&campaign=141805378&geo=90562&kw=astrocytoma&query=astrocytoma&ad=80676678745550&network=Search&sitetarget=o&adgroup=4634137820&extension=&target=&matchtype=e&device=c&account=B013932Y&invsrc=neuro&placementsite=enterprise&msclkid=2dd7e90454fc169dba83b216fb142084

Protoplasmic astrocytoma definition | Drugs.comProtoplasmic astrocytoma definition | Drugs.com

Definition of protoplasmic astrocytoma. Provided by Stedmans medical dictionary and Drugs.com. Includes medical terms and ...
more infohttps://www.drugs.com/dict/protoplasmic-astrocytoma.html

Low-Grade Astrocytoma Differential DiagnosesLow-Grade Astrocytoma Differential Diagnoses

Low-grade astrocytomas are a heterogeneous group of intrinsic central nervous system (CNS) neoplasms that share certain ... Low-Grade Astrocytoma Differential Diagnoses. Updated: Dec 21, 2017 * Author: George I Jallo, MD; Chief Editor: Tarakad S ... encoded search term (Low-Grade%20Astrocytoma) and Low-Grade Astrocytoma What to Read Next on Medscape. Medscape Consult. ... Morantz R A. Low-grade astrocytomas. Kaye AH, Laws ER Jr, eds. Brain Tumors: An Encyclopedic Approach. New York: Churchill ...
more infohttps://emedicine.medscape.com/article/1156429-differential

Pilocytic astrocytoma/glioma - Neurology - MedHelpPilocytic astrocytoma/glioma - Neurology - MedHelp

Pilocytic astrocytoma/glioma CancerTumor If someone has had chemotherapy treatments for the above mentioned (brain) tumor, does ... Pilocytic astrocytoma and glioma are benign tumors of the brain and may or may not be cancerous which means these tumors ... Pilocytic astrocytoma and glioma are benign tumors of the brain and may or may not be cancerous which means these tumors ... Pilocytic astrocytoma/glioma. If someone has had chemotherapy treatments for the above mentioned (brain) tumor, does it mean he ...
more infohttps://www.medhelp.org/posts/Neurology/Pilocytic-astrocytoma-glioma/show/796383

Retinal Astrocytoma - American Academy of OphthalmologyRetinal Astrocytoma - American Academy of Ophthalmology

Retinal Astrocytoma Written By: Cristina Moreira dos Santos, MD, Inês Coutinho, MD, and Susana Teixeira, MD, and photographed ... Because retinal astrocytoma is often associated with tuberous sclerosis, a workup for tuberous sclerosis was performed, ... A presumptive diagnosis of retinal astrocytoma, a low-grade neoplasm of retinal origin, was established. ...
more infohttps://www.aao.org/eyenet/article/retinal-astrocytoma

Low-Grade Astrocytoma Medication: Anticonvulsants, CorticosteroidsLow-Grade Astrocytoma Medication: Anticonvulsants, Corticosteroids

Low-grade astrocytomas are a heterogeneous group of intrinsic central nervous system (CNS) neoplasms that share certain ... encoded search term (Low-Grade Astrocytoma) and Low-Grade Astrocytoma What to Read Next on Medscape. Related Conditions and ... Low-Grade Astrocytoma Medication. Updated: Dec 21, 2017 * Author: George I Jallo, MD; Chief Editor: Tarakad S Ramachandran, ... Morantz R A. Low-grade astrocytomas. Kaye AH, Laws ER Jr, eds. Brain Tumors: An Encyclopedic Approach. New York: Churchill ...
more infohttps://emedicine.medscape.com/article/1156429-medication

Anaplastic astrocytoma - WikipediaAnaplastic astrocytoma - Wikipedia

Anaplastic astrocytoma is a rare WHO grade III type of astrocytoma, which is a type of cancer of the brain. In the United ... Anaplastic Astrocytoma. Retrieved on August 2010 Malignant astrocytomas By Edward J Dropcho MD. Contributing editor: Dr. ... Anaplastic astrocytomas have also been associated with previous exposure to vinyl chloride and to high doses of radiation ... Compared to grade II tumors, anaplastic astrocytomas are more cellular, demonstrate more atypia, and mitoses are seen. Initial ...
more infohttps://en.wikipedia.org/wiki/Anaplastic_astrocytoma

Pilocytic astrocytoma - WikipediaPilocytic astrocytoma - Wikipedia

Pilocytic astrocytoma or juvenile pilocytic astrocytoma or cystic cerebellar astrocytoma (and its variant juvenile pilomyxoid ... About 80-85% of cerebellar astrocytomas are juvenile pilocytic astrocytomas. Recent genetic studies of pilocytic astrocytomas ... Grade II astrocytomas and cerebellar gliomas are more likely to recur after surgical removal. Pilomyxoid astrocytomas may ... The majority of pilocytic astrocytomas have a unique KIAA1549-BRAF fusion gene. Children affected by pilocytic astrocytoma can ...
more infohttps://en.wikipedia.org/wiki/Pilocytic_astrocytoma

Positional vertigo with cerebellar astrocytoma.  - PubMed - NCBIPositional vertigo with cerebellar astrocytoma. - PubMed - NCBI

Positional vertigo with cerebellar astrocytoma.. Gregorius FK, Crandall PH, Baloh RW.. Abstract. The authors present two ... surgically verified cases of cerebellar astrocytoma extending into the fourth ventricular floor. Each patient presented with ...
more infohttps://www.ncbi.nlm.nih.gov/pubmed/996727

Astrocytoma - Childhood: Introduction | Cancer.NetAstrocytoma - Childhood: Introduction | Cancer.Net

This is the first page of Cancer.Nets Guide to Childhood Astrocytoma. Use the menu to see other pages. Think of that menu as a ... Astrocytoma can occur throughout the CNS, including in the following places:. * The cerebellum, which is the back part of the ... Astrocytoma is a type of CNS tumor that forms in cells called astrocytes. Healthy astrocytes provide the connecting network of ... This is the first page of Cancer.Nets Guide to Childhood Astrocytoma. Use the menu to see other pages. Think of that menu as a ...
more infohttps://www.cancer.net/cancer-types/astrocytoma-childhood/introduction

Briana-Anaplastic Astrocytoma (Brain Cancer) | Sandi Drummonds FundraiserBriana-Anaplastic Astrocytoma (Brain Cancer) | Sandi Drummond's Fundraiser

3 LITTLE BIRDS 4 LIFE wrote - My name is Briana, and I was diagnosed with a rare brain cancer called Anaplastic Asterocytoma. Stage three brain cancer. I am 24 years, and I am the mother of a five year old little girl named Angelina. My dream in life is to be a cop, and I had done 6 1/2 weeks of Proton Raidation , along with chemo everyday for the 6 1/2 weeks. I am currently doing chemo five days per month, and I had surgery in November 2012 I had the whole right temporal lobe of the brain removed. I know is I just want to be cancer free, and I pray to beat the odds of this deadly disease because, I believe I have more to share with this world, and my journey is not done here if possible a cure my real wish is to have a cure for cancer. I just want to enjoy every day/night being happy, and also for my mother to be happy also because, she has done so much for me, and my child she deserves a vacation she is a mother of six, and I know as a mother
more infohttps://www.crowdrise.com/brianah/fundraiser/sandidrummond

Astrocytoma - Childhood: Risk Factors | Cancer.NetAstrocytoma - Childhood: Risk Factors | Cancer.Net

You will find out more about the factors that increase the chance of developing astrocytoma. Use the menu to see other pages.A ... Astrocytoma - Childhood: Risk Factors. Approved by the Cancer.Net Editorial Board, 02/2019 ... ON THIS PAGE: You will find out more about the factors that increase the chance of developing astrocytoma. Use the menu to see ... It explains what body changes or medical problems astrocytoma can cause. Use the menu to choose a different section to read in ...
more infohttps://www.cancer.net/cancer-types/astrocytoma-childhood/risk-factors

Astrocytoma | Boston Childrens HospitalAstrocytoma | Boston Children's Hospital

Learn more about astrocytoma symptoms, diagnosis, and treatments from experts at Boston Childrens, ranked best Childrens ... Most astrocytomas are both highly treatable and highly curable. The most common kind of astrocytoma, called a pilocytic ... Astrocytoma Treatment at Dana-Farber/Boston Childrens. Children and adolescents with astrocytomas are treated at Dana-Farber/ ... Grades 1 and 2 are considered low-grade astrocytomas, and grades 3 and 4 are considered high-grade astrocytomas. ...
more infohttp://www.childrenshospital.org/conditions-and-treatments/conditions/c/cerebellar-lowgrade-astrocytoma/overview

Dietary Restriction Promotes Vessel Maturation in a Mouse AstrocytomaDietary Restriction Promotes Vessel Maturation in a Mouse Astrocytoma

Figure 5: Dietary restriction reduces PDGF-Rβ and VEGF-R2 association in the CT-2A astrocytoma. (a) Confocal analysis of CT-2A ... Figure 3: Dietary restriction increases α-SMA and reduces Factor VIII expression in the CT-2A astrocytoma. The histograms show ... Dietary Restriction Reduces PDGF-Rβ and VEGF-R2 Association in the CT-2A Astrocytoma. Confocal microscopy showed that the ... We found for the first time that DR could enhance tumor blood vessel maturation in a malignant mouse astrocytoma. DR not only ...
more infohttps://www.hindawi.com/journals/jo/2012/264039/

31 year old son with astrocytoma | DailyStrength31 year old son with astrocytoma | DailyStrength

My youngest son has a recurring astrocytoma. He has undergone 2 resections in two years. It appears the tumor has reoccurred. ... My youngest son has a recurring astrocytoma. He has undergone 2 resections in two years. It appears the tumor has reoccurred. ...
more infohttps://www.dailystrength.org/group/brain-cns-tumors/discussion/31-year-old-son-with-astrocytoma

Astrocytoma at 20x Magnification | MicroscopyUAstrocytoma at 20x Magnification | MicroscopyU

In children, the majority of astrocytomas that occur are classified as low-grade, but in adults most of the tumors are of the ... Like all brain tumors, astrocytomas are very serious and are usually described by the medical community based upon their grade ... The most advanced astrocytomas (grade IV) are usually described as glioblastoma multiforme. ... Astrocytomas are the most common variety of glioma (tumor that arises from glial cells) and may be benign or malignant. ...
more infohttps://www.microscopyu.com/gallery-images/astrocytoma-at-20x-magnification

Search of: Subependymal giant cell astrocytoma - List Results - ClinicalTrials.govSearch of: 'Subependymal giant cell astrocytoma' - List Results - ClinicalTrials.gov

Study of Blood Samples and Risk of Infection in Patients With Newly Diagnosed Malignant Supratentorial Astrocytoma. *Brain and ... Efficacy and Safety of Everolimus (RAD001) in Patients of All Ages With Subependymal Giant Cell Astrocytoma Associated With ... Everolimus (RAD001) Therapy of Giant Cell Astrocytoma in Patients With Tuberous Sclerosis Complex. *Tuberous Sclerosis ... Percentage of Participants With Best Overall Subependymal Giant Cell Astrocytomas (SEGA) Response ...
more infohttps://clinicaltrials.gov/ct2/results?cond=%22Subependymal+giant+cell+astrocytoma%22&show_rss=Y&sel_rss=new14

Brain Tumor (Astrocytoma) in Dogs | petMDBrain Tumor (Astrocytoma) in Dogs | petMD

Astrocytomas are brain tumors that affect the organs glial cells, which surround nerve cells (neurons), giving them support ... However, an astrocytoma can also be rarely found in the spinal cord, and there was one reported case of an astrocytoma located ... Astrocytoma in Dogs. Astrocytomas are brain tumors that affect the organs glial cells, which surround nerve cells (neurons), ... The astrocytomas biologic behavior depends on the tumors location and degree of lack of cell differentiation (graded I-IV, ...
more infohttps://www.petmd.com/dog/conditions/neurological/c_dg_astrocytoma

Astrocytoma brain tumor survivor: I feel lucky | MD Anderson Cancer CenterAstrocytoma brain tumor survivor: I feel lucky | MD Anderson Cancer Center

When Kellilyn Monar was diagnosed with an astrocytoma, her father said they only had once chance to make the best decision ... When Kellilyn Monar was diagnosed with an astrocytoma, her father said they only had once chance to make the best decision ... She had her biopsy in Las Vegas, and learned it was a grade II astrocytoma. But Kellilyn wasnt comfortable moving forward with ...
more infohttps://www.mdanderson.org/publications/cancerwise/astrocytoma-brain-tumor-survivor--i-feel-lucky.h00-159301467.html

Gene Expression Profiling in Human High-Grade AstrocytomasGene Expression Profiling in Human High-Grade Astrocytomas

... Zhongyu Liu,1 Zhiqiang Yao,2 Chao Li,3 Yicheng Lu,4 and Chunfang ... Zhongyu Liu, Zhiqiang Yao, Chao Li, Yicheng Lu, and Chunfang Gao, "Gene Expression Profiling in Human High-Grade Astrocytomas ...
more infohttps://www.hindawi.com/journals/ijg/2011/245137/cta/

Vesalius Clinical Folios: AstrocytomaVesalius Clinical Folios: Astrocytoma

Stereotactic biopsy revealed an anaplastic (high grade, 3) astrocytoma. Notes:. Link to this frame from your Personal ...
more infohttp://vesalius.com/cfoli_frms.asp?VID=862&StartFrame=1&tnVID=863

Astrocytoma: Grade IV | GreenMedInfo | Disease | Natural MedicineAstrocytoma: Grade IV | GreenMedInfo | Disease | Natural Medicine

Diseases : Astrocytoma, Astrocytoma: Grade IV, Brain Cancer, Glioma. Additional Keywords : Tissue Inhibitors of ... 1 Abstracts with Astrocytoma: Grade IV Research. Filter by Study Type. Human: Case Report. ...
more infohttp://www.greenmedinfo.com/disease/astrocytoma-grade-iv

Anaplastic Astrocytoma Symptoms & Causes | Boston Childrens HospitalAnaplastic Astrocytoma Symptoms & Causes | Boston Children's Hospital

Learn about Anaplastic Astrocytoma symptoms and causes from experts at Boston Childrens, ranked best Childrens Hospital by US ...
more infohttp://www.childrenshospital.org/conditions-and-treatments/conditions/anaplastic-astrocytoma/symptoms-and-causes

Anaplastic Astrocytoma Pipeline Analysis and Outlook, 2019Anaplastic Astrocytoma Pipeline Analysis and Outlook, 2019

Anaplastic Astrocytoma pipelineAnaplastic Astrocytoma pipeline research report is a part of our 300+ Pharmaceutical and ... Anaplastic Astrocytoma pipeline. Anaplastic Astrocytoma pipeline research report is a part of our 300+ Pharmaceutical and ... Anaplastic Astrocytoma pipeline report enables users to gain clear understanding into large and small companies participating ... The guide presents also available opportunities for new business in Anaplastic Astrocytoma treatment pipeline.. The report ...
more infohttps://www.reportlinker.com/p05778022/Anaplastic-Astrocytoma-Pipeline-Analysis-and-Outlook.html
  • Expression and prognostic value of NDRG2 in human astrocytomas," Journal of the Neurological Sciences , vol. 308, no. 1-2, pp. 77-82, 2011. (hindawi.com)
  • These findings suggest that the PI3K/PTEN/AKT pathway is critical for formation of malignant astrocytomas and support the hypothesis of neural stem cell origin for human astrocytomas. (aacrjournals.org)
  • Differential expression of two fibroblast growth factor-receptor genes is associated with malignant progression in human astrocytomas. (pnas.org)
  • In this study, we demonstrated that human astrocytomas undergo parallel changes in FGF-receptor (FGFR) expression during their progression from a benign to a malignant phenotype. (pnas.org)
  • mRNA expression of seven different stem cell markers (CD133, Nestin, SOX-2, Musashi-1, Flt-4, Endoglin and CXCR4) was examined in normal brain tissue (NBT) and human astrocytomas of different WHO grades using real-time reverse transcription polymerase chain reaction. (egms.de)
  • The aggressiveness (grade) of your astrocytoma determines your prognosis and treatment options. (mayoclinic.org)
  • In all, it seems that the B7-H6 expression might be a marker to differentiate the World Health Organization grade level of astrocytoma, but the prognosis value of B7-H6 in astrocytoma should be studied in detail. (dovepress.com)
  • Gene mutations, such as 1p19q and IDH132, affect the prognosis of anaplastic astrocytoma and should, therefore, be tested to guide therapy [ 1 - 2 , 5 ]. (pubmedcentralcanada.ca)
  • A growing body of epidemiologic and molecular research has identified an important role of genomic and epigenomic alterations in astrocytoma initiation, susceptibility, and prognosis. (jcancer.org)
  • Conversely, FGFR type 1 (FLG) expression was absent or barely detectable in normal white matter but was significantly elevated in malignant astrocytomas. (pnas.org)
  • AREG was also designated to be a promising marker for several types of cancer however precious little data about AREG role in the most frequent and generally lethal human brain tumours - astrocytomas reported up to date. (jcancer.org)
  • Kaplan-Meier analysis encompassing only malignant tumours showed similar results indicating that AREG is associated with astrocytoma patient survival independently from astrocytoma grade. (jcancer.org)
  • Astrocytomas are the most common types of primary brain tumours accounting for approximately 13.3% of all newly diagnosed brain tumours. (egms.de)
  • Previously, we reported a mouse model for malignant astrocytomas, in which germline haploinsufficiency of p53 and conditional haploinsufficiency of Nf1 tumor suppressors on the same chromosome induce the malignancy with complete penetrance (Mut3 mice in Zhu et al. (aacrjournals.org)
  • These features are significant in measuring the malignancy of an astrocytoma with regard to its invasion and developmental pace. (brain-surgery.com)
  • The aim of the study was to investigate how AREG changes at epigenetic and expression levels reflect on astrocytoma malignancy and patient outcome. (jcancer.org)
  • Current findings demonstrate that AREG appearance is associated with patient survival as well as astrocytomas malignancy indicating its influence on tumour progression and suggest its applicability as a promising marker. (jcancer.org)
  • We therefore chose to express the P2Y12 receptor in 1321N1 astrocytoma cells, which have minimal endogenous receptor. (creative-biogene.com)
  • In many cases, patients with anaplastic astrocytoma may experience various types of paralysis, speech impediments, difficulties planning and skewed sensory perception. (wikipedia.org)
  • Grade-specific expression of insulin-like growth factor-binding proteins-2, -3, and -5 in astrocytomas: IGFBP-3 emerges as a strong predictor of survival in patients with newly diagnosed glioblastoma," Cancer Epidemiology Biomarkers & Prevention , vol. 19, no. 6, pp. 1399-1408, 2010. (hindawi.com)
  • Determine the antitumor activity of antineoplastons A10 and AS2-1 in children with low-grade astrocytoma by determining the proportion of patients who experience an objective tumor response. (knowcancer.com)
  • The B7-H6 expression did not show significant relevance with patient age, sex distribution, Karnofsky performance status score, extent of resection, and tumor location in astrocytoma patients, but B7-H6 positive expression is significantly associated with World Health Organization grade ( P =0.046). (dovepress.com)
  • However, the survival rate after operation presented no significant difference of B7-H6 expression in astrocytoma patients. (dovepress.com)
  • Management of choice for patients with low grade astrocytoma is still not clear and is controversial9-11. (thefreedictionary.com)
  • Because of the promising results in preliminary studies of Erlotinib and because of significant experience with the safety of the dosages proposed in this study, this study will offer a safe adjuvant treatment for patients with relapsing recurring glioblastoma or anaplastic astrocytoma. (knowcancer.com)
  • Hi Keithga: I do not check into this site too often these days, but when I do I look for posts by people with astrocytomas stage 2 as there is much less info out there for such patients. (cancercompass.com)
  • Burkhard C, Di Patre PL, Schuler D, Schuler G, Yasargil MG, Yonekawa Y, Lutolf UM, Kleihues P, Ohgaki H. A population-based study of the incidence and survival rates in patients with pilocytic astrocytoma. (springermedizin.de)
  • Steponaitis G, Kazlauskas A, Skiriute D, Vaitkiene P, Skauminas K, Tamasauskas A. Significance of Amphiregulin (AREG) for the Outcome of Low and High Grade Astrocytoma Patients. (jcancer.org)
  • This is the first page of Cancer.Net's Guide to Childhood Astrocytoma. (cancer.net)
  • Expert-reviewed information summary about the treatment of childhood astrocytomas. (oncolink.org)
  • This PDQ cancer information summary for health professionals provides comprehensive, peer-reviewed, evidence-based information about the treatment of childhood astrocytomas. (oncolink.org)
  • Larson DA, Wara WM, Edwards MS (1990) Management of childhood cerebellar astrocytoma. (springer.com)
  • PubMed is a searchable database of medical literature and lists journal articles that discuss Cerebral astrocytoma, childhood. (nih.gov)
  • The addition of fixed PC12 cells or plasma membranes purified from PC12 cells, 3T3 cells, or astrocytoma cells had no effect on glial cell growth. (jneurosci.org)
  • To investigate the putative adaptive changes in antioxidant enzyme protein expression and targeting to mitochondria as mtDNA depletion occurs, we progressively depleted U87 astrocytoma cells of mtDNA by chronic treatment with ethidium bromide (EB, 50 ng/ml). (springer.com)
  • Rapid, specific binding of granule neurons to the human A-172, HTB-16, and U-251 and mouse G26-24 cell lines occurred, after which 3H-thymidine incorporation by these astrocytoma cells dropped 2-5-fold within 12 hr. (jneurosci.org)
  • Pilomyxoid astrocytomas are composed of monomorphous bipolar cells with a prominent angiocentric pattern. (radiopaedia.org)
  • Knockdown of STAT3 expression by RNAi induces apoptosis in astrocytoma cells. (tufts.edu)
  • Protein kinase C activators sensitize cyclic AMP accumulation by intact 1321N1 human astrocytoma cells. (aspetjournals.org)
  • Pretreatment of 1321N1 human astrocytoma cells with phorbol 12-myristate-13-acetate or other activators of protein kinase C led to 2.5- to 5-fold increases (sensitization) in subsequent stimulation by forskolin of intracellular cyclic AMP accumulation. (aspetjournals.org)
  • In relation to NBT high CD133, Nestin, SOX-2, and Musashi-1 mRNA expression levels and amounts of positive stained cells could be observed especially in astrocytomas of WHO grade IV. (egms.de)
  • While also great quantities of Nestin positive cells could be detected in high malignant astrocytomas, the percentage of CD133 positive cells was lower than that of Nestin but higher than that of SOX-2 and Musashi-1. (egms.de)
  • Correlation analysis determined positive correlations between the percentages of Nestin, CD133, SOX-2, and Musashi-1 immunoassayed cells and the pathological grades of astrocytomas. (egms.de)
  • elongated cells with fibrillary processes Gemistocytic astrocytoma. (thekickstandllc.com)
  • Astrocytoma is more commonly referred to as either high grade or low grade (see Stages and Grades ). (cancer.net)
  • WHO's histological guidelines categorize the grades of astrocytoma into four levels. (brain-surgery.com)
  • Therefore, we performed CNA profiling of 65 astrocytomas of distinct malignant grades (WHO grade I-IV) of Brazilian origin, using array-CGH and microsatellite instability analysis (MSI), and investigated their correlation with TERT and IDH1 mutational status and clinico-pathological features. (g3journal.org)
  • These results demonstrated a complex gene expression pattern of putative tumour stem cell markers in astrocytomas of different WHO grades. (egms.de)
  • A presumptive diagnosis of retinal astrocytoma, a low-grade neoplasm of retinal origin, was established. (aao.org)
  • Endothelial Proliferation - The intensity of penetration of the neoplasm into the endothelium layer is a decisive factor in deciding the grade of an Astrocytoma. (brain-surgery.com)